

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Predictors of HIV Virologic Failure And Drug Resistance In Chinese Patients After 48 Months Of Antiretroviral Treatment, 2008-2012

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016012
Article Type:	Research
Date Submitted by the Author:	21-Jan-2017
Complete List of Authors:	<p>Kan, Wei; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China; Emory University School of Public Health, Department of Epidemiology</p> <p>Teng, Tao; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China</p> <p>Liang, Shujia; Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention</p> <p>Ma, Yanling; Yunnan Center for Disease Control and Prevention, Kunming, China,</p> <p>Tang, Heng; Hubei Center for Disease Control and Prevention</p> <p>Zuohela, Tuerdi; Xinjiang Uighur Autonomous Region Center for Disease Control and Prevention</p> <p>Sun, Guoqing; Henan Province Center for Disease Control and Prevention</p> <p>He, Cui; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China,</p> <p>Wall, Kristin; Emory University School of Public Health, Department of Epidemiology</p> <p>Marconi, Vincent; Emory University School of Public Health, Department of Global Health; Emory University School of Medicine, Division of Infectious</p> <p>Liao, Lingjie; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China,</p> <p>Leng, Xuebing; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China,</p> <p>Liu, Pengtao ; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China</p> <p>Ruan, Yuhua; Chinese Center for AIDS/STD Control and Prevention, Division of Virology and Immunology</p> <p>Xing, Hui; State Key Laboratory for Infectious Disease Prevention and</p>

	Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China, Shao, Yiming; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	Public health
Keywords:	Antiretroviral Treatment, Virological Failure, Drug Resistance, Gender Difference, HIV & AIDS < INFECTIOUS DISEASES>

SCHOLARONE™
Manuscripts

**Predictors of HIV Virologic Failure And Drug Resistance In Chinese Patients
After 48 Months Of Antiretroviral Treatment, 2008-2012**

Wei Kan^{1,7*}, Tao Teng^{1*}, Shujia Liang², Yanling Ma³, Heng Tang⁴, Tuerdi
Zuohela⁵, Guoqing Sun⁶, Cui He¹, Kristin M. Wall⁷, Vincent C. Marconi^{8,9}, Lingjie
Liao¹, Xuebing Leng¹, Pengtao Liu¹, Yuhua Ruan¹, Hui Xing¹, Yiming Shao¹

1. State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China
2. Guangxi Center for Disease Control and Prevention, Nanning, China
3. Yunnan Center for Disease Control and Prevention, Kunming, China
4. Hubei Center for Disease Control and Prevention, Wuhan, China
5. Xinjiang Autonomous Region Center for Disease Control and Prevention, Urumqi, China
6. Henan Center for Disease Control and Prevention, Zhengzhou, China
7. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
8. Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia.
9. Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia

*These authors contributed equally to this work

Running head: Virologic failure and drug resistance among HIV+ Chinese ART patients

Body: 3,111

ABSTRACT

Objective: To explore factors associated with HIV virologic failure (VF) and HIV drug resistance (HIVDR) among HIV-positive Chinese individuals four years after initiating first-line 3TC-based antiretroviral treatment (ART) in 2008 at five sentinel sites.

Design: First-line ART initiators who were previously treatment naïve were selected using consecutive ID numbers from the 2008 National Surveillance Database into a prospective cohort study. Questionnaires and Blood samples were collected in 2011 and 2012 to assess the outcomes of interest: VF (defined as viral load ≥ 1000 copies/ml) and HIVDR (defined as VF with genetic drug resistant mutations). Questionnaires and data from National Surveillance Database assessed demographics and drug adherence data.

Results: 536 individuals with HIV were analyzed; the 4-year risk of VF was 63(11.8%) and HIVDR was 27(5.0%). Female participants initiating D4T-based regimens were more susceptible to both VF (adjusted odds ratio, aOR=2.5 95% CI: 1-6.1 P-value=0.04) and HIVDR (aOR=3.6 95% CI: 1 to 12.6 P-value=0.05) versus AZT-based regimens. Male participants missing doses in past month were more susceptible to both VF (aOR=2.8 95% CI: 1.1 to 7.X P-value=0.03) and HIVDR (aOR=9.7 95% CI: 2.1 to 44.1 P-value<0.01). Participants of non-Han nationality were of increased risk for HIVDR (aOR from 4.8-12.2, p<0.05) and non-Han men were at increased risk for VF (aOR = 2.9, p=0.02). All 27 participants detected with HIVDR had non-

1
2
3
4 nucleoside reverse-transcriptase inhibitor (NNRTI) mutations, 21 (77.8%) also had
5
6 NRTI mutations, and no protease inhibitor mutations were detected.
7
8

9 **Conclusions:** Our findings suggest successful treatment outcomes at 4-years for
10
11 roughly 90% of patients. We found female participants initiating D4T versus AZT-
12
13 based regimens were more vulnerable to VF and HIVDR, while poor adherence was a
14
15 risk factor among male participants. Increased VF and HIVDR risk among non-Han
16
17 minorities warrants further exploration, and ethnic minorities may be an important
18
19 group to tailor adherence-focused interventions in China.
20
21
22
23

24 25 **Strengths and limitations of this study**

- 26
27
28 ▪ We studied 48-month risk of VF and HIVDR and their associations with
29
30 demographic and behavioral information among individuals across five
31
32 sentinel sites.
33
34
- 35
36 ▪ Drug adherence and adverse effects influenced VF and HIVDR differently
37
38 across gender, however, the reasons for the differences were uncertain in the
39
40 study.
41
42
- 43
44 ▪ The outcomes were measured in 2011 and 2012, and thus we may be missing
45
46 transient VF outcomes.
47
48
49
50
51
52
53

54
55 **Key words:** HIV, Antiretroviral Treatment, Virological Failure, Drug Resistance,
56
57 Gender Differences, China
58
59
60

Corresponding author:

Yiming Shao

State Key Laboratory for Infectious Disease Prevention and Control, and National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China

No. 155 Changbai Road, Changping District, Beijing 102206, P. R. China

Telephone: + 86-10-58900647 Fax: +86-10-58900980

E-mail: yshao@bjmu.edu.cn

Introduction

Antiretroviral treatment (ART) has dramatically improved health outcomes and decreased HIV-associated morbidity and mortality through virologic suppression and subsequent CD4 recovery.¹⁻⁴ In 2003, China launched a National Free Antiretroviral Treatment Program (NFATP) that includes life-long provision of free ART for people living with HIV who met the national treatment criteria.^{5 6} The national treatment criteria from 2008 to 2011 were: (1) CD4 cell count $\leq 200/\text{mm}^3$; (2) World Health Organization (WHO) stage III/IV diseases; or (3) willingness to receive ART, regardless of criteria 1 and 2.⁷

The State Council AIDS Working Committee Office and the United Nations Theme Group on AIDS estimated that there were more than 700,000 persons living with HIV in China in 2008, and more than 52,000 individuals with HIV across 31 provinces, autonomous regions, and municipalities had received ART (made freely available by the NFATP) by August 2008.⁸

With the rapid scale-up of treatment and challenges with adherence, virologic failure (VF) and HIV drug resistance (HIVDR) are ever present and mounting concerns.

Incomplete virologic suppression, a major cause of HIVDR, not only compromises therapeutic efficacy for the individual receiving treatment, increasing the risk of viral rebound and opportunistic infections, but also increases the risk of transmitting drug resistant strains to other individuals in the general population.^{9 10 11}

1
2
3
4 Observational studies in China have documented the prevalence of VF and HIVDR
5
6 strains among treated individuals living with HIV. A cross-sectional study conducted
7
8 in Yunnan, Guangxi and Xinjiang provinces in 2010 stated that one-year HIVDR
9
10 prevalence was 75.3% and 4.1%⁵. VF prevalence for sexual transmitted population
11
12 and intravenous drug users (IDUs) were 8.3% and 19.3%, separately. A 6-year
13
14 follow-up study in 2010 suggested an incidence of 14.1 per 100 person-year for VF
15
16 and 11.9 per 100 person-year for HIVDR among former plasma donors in Anhui
17
18 Province.¹²

19
20 NFATP recommended to switch the first-line regimen from Didanosine (DDI) to
21
22 Lamivudine (3TC) in 2008, and there are few nationwide, prospective studies in
23
24 China reporting frequency or predictors of VF and HIVDR for people after initiating
25
26 3TC based regimens.

27
28 The aim of this study is to evaluate predictors of VF and HIVDR in a prospective
29
30 cohort of Chinese HIV individuals with HIV four years after first initiating first-line
31
32 3TC-based ART in 2008 at five sentinel sites. We stratified our analyses by gender
33
34 based on conflicting findings on gender differences both in virological responses and
35
36 drug resistance to different ART regimen, as well as gender differences in ART
37
38 adherence.¹³⁻¹⁶ To our knowledge, this is the first long-term study to evaluate VF and
39
40 HIVDR on 3TC-based regimens.

41 42 43 44 45 46 47 48 49 50 51 52 53 54 **Ethics Statement**

1
2
3
4 The study was approved by the institutional review board (IRB) of the National
5
6 Center for AIDS/STD Control and Prevention of the China Center for Disease Control
7
8 Prevention (NCAIDS, China CDC). All participants provided written informed
9
10 consent before participation.
11
12

13 14 **Study Design and Data Collection**

15
16
17
18 This study was designed under the WHO Surveillance of HIV drug resistance in
19
20 adults receiving ART for 48 months.^{10 17 18}
21
22

23
24 Five provinces in China were selected to conduct a prospective cohort study with a
25
26 follow-up study at 12 months: Guangxi, Henan, Hubei, Xinjiang and Yunnan. Patients
27
28 were sampled from the 2008 National HIV Surveillance Database. Participant
29
30 eligibility criteria included being age ≥ 18 years; having initiated NAFTP-sponsored
31
32 first-line ART in 2008; having been ART-free before 2008; having been on ART for
33
34 36 \pm 6 months in 2011; and providing consent to participate in the study.
35
36
37

38
39 Questionnaires administered by trained study personnel using structured interviews
40
41 collected data in 2011 and 2012. Additional HIV-specific data including route of
42
43 transmission, initial ART regimen, latest ART regimen, ART distribution location and
44
45 CD4 cell count were collected from the 2011-2012 National HIV Surveillance
46
47 Database. There was no missing demographic data, missed questionnaire data was
48
49 feedback to local CDC for recollection at the time.
50
51
52
53
54
55
56
57
58
59
60

Laboratory analysis

Blood specimens were collected from all participants to test CD4 cell count, HIV-1 RNA viral load (VL), and HIV-1 drug resistance mutations in 2011 and 2012. Plasma was isolated and stored at -80°C at a provincial CDC laboratory and then transferred to NCAIDS. CD4 cell count estimation was conducted at CDC laboratories using flow cytometry (FACSC Calibur, BD Company, USA) within 24 hours after specimen collection.

Plasma HIV RNA was quantified with real-time NASBA (NucliSense Easy Q, bioMerieux, France) or COBAS (Roche Applied Biosystems, Germany) according to manufacturer recommendations using in-house PCR (polymerase chain reaction).¹⁹ Virologic failure was defined as VL \geq 1000 copies/ml. According WHO protocol,²⁰ HIVDR tests were performed on samples with VL \geq 1000 copies/ml. HIV-1 *pol* gene (protease 1-99 amino acids and part of reverse transcriptase 1-252 amino acids) were amplified, purified and analyzed using the Stanford HIV Drug Resistance Database (<http://hivdb.stanford.edu/>). Any low-, intermediate-, or high-level resistance identified was defined as HIVDR.²¹⁻²⁴ HIV VL and drug resistance mutation testing was conducted at NCAIDS.

Data analysis

1
2
3
4 Questionnaire data were double-entered using Epidata 3.1 (The Epidata Association
5
6 Odense, Denmark). Statistical Analysis System (SAS 9.4, SAS Institute Inc., Cary,
7
8 NC, USA) was then used for data cleaning and analyses.
9

10
11 48-month risk for the outcomes of interest was calculated as the proportion of unique
12
13 persons who had experienced incident VF or HIVDR by the end of follow-up in 2012.
14

15
16 Covariates of interest were described using counts and percentages overall and by the
17
18 outcome of interest, stratified by gender. Univariate logistic regression models were
19
20 constructed to explore associations between covariates of interest and VF or HIVDR.
21
22

23
24 Odds ratios (OR) and 95% confidence intervals (CIs) are reported. Variables that
25

26
27 were significant ($P < 0.05$) in the univariate models were then fit into multivariate
28

29
30 logistic regression models assessment for/removal of collinear variables that had the
31

32
33 weakest association with the outcome. Adjusted ORs (aOR) and 95% CIs were
34

35
36 presented. $P < 0.05$ was defined as statistically significant, and all tests were two
37

38
39 sided. Descriptive analysis on HIVDR mutation results was conducted among 27
40

41
42 HIVDR participants, stratified by sex.
43

44 **Results**

45
46 1100 subjects were selected using consecutive ID numbers from 2008 National
47

48
49 Surveillance Database; of those, 490 were lost follow-up by December, 2012. Among
50

51
52 those lost to follow up, 139 died, 55 emigrated, 134 lost contact, 17 refused to
53

54
55 participate, 65 stopped ART before 30 months, 36 transferred, 8 were under custody,
56

57
58 6 failed to provide a blood sample, 3 switched from ART to Tangcao tablet (an
59
60

1
2
3
4 antiviral Chinese herbal therapy), 2 became pregnant and switched to other regimens
5
6 and 1 was paralyzed. After excluding 74 participants for failing the eligibility criteria,
7
8
9 536 participants were included in the final 24-month analysis (Figure 1). The 48-
10
11 month risk of VF was 11.8% and risk of drug resistance was 5%.
12

13 14 15 16 17 Demographic and ART Information (Tables 1-2)

18
19 Of the 536 eligible participants, 51.8% were male; 76.5% were Han majority; 45.0%
20
21 had an education level of elementary school or less; 56.2% were farmers; and 10.6%
22
23 were unemployed with the rest having regular income.
24
25

26
27 All regimens in this cohort were 3TC-based. Initiated Nucleoside Reverse
28
29 Transcriptase Inhibitors (NRTI) regimens included Zidovudine (AZT) (n=349, 65.1%)
30
31 or Stavudine (D4T) (n=187, 34.9%). Sixty-six (12.3%) participants later changed to
32
33 TDF based regimen. Initiated Non-Nucleoside Reverse Transcriptase Inhibitors
34
35 (NNRTI) regimens included Nevirapine (NVP) (n=421, 78.5%) or Etravirine (EFV)
36
37 (n=115, 21.5%). Fifty-five (10.3%) participants later changed to LPV/r based regimen.
38
39 169 (31.5%) participants switched the initial ART regimen during 2008-2012, but no
40
41 statistical significant difference was found in VF and HIVDR risk between
42
43 participants who switched regimens and participants who did not switch regimens.
44
45
46 We found that 38.4% participants were hesitant to accept ART in the future, 36.8%
47
48 participants reported doubts whether ART was health promoting and 42.5%
49
50 participants did not report that poor ART adherence necessarily contributed to
51
52
53
54
55
56
57
58
59
60

1
2
3
4 HIVDR. Additionally, 40.5% of participants were not always satisfied with support
5
6 from friends or relatives. 472 (88.1%) participants reported not missing a dose in the
7
8 month prior to the date of the survey.
9

10 11 12 13 14 Multivariate model results (Table 3)

15
16 As shown in Table 3, minority male participants were at higher risk for both VF
17
18 (aOR=2.9 95% CI: 1.1 to 7.3 P-value=0.02) and HIVDR (aOR=12.2 95% CI: 1.8 to
19
20 84.8 P-value=0.01) compared to Han majority male participants, while female
21
22 minorities were only at a higher risk for HIVDR (aOR=4.8 95% CI: 1.2 to 19.7 P-
23
24 value=0.03).
25
26
27
28

29
30 Female participants initiating D4T-based regimens were at a higher risk for both VF
31
32 (aOR=2.5 95% CI: 1 to 6.1 P-value=0.04) and HIVDR (aOR=3.6 95% CI: 1 to 12.6
33
34 P-value=0.05) versus those initiating an AZT-based regimen; interestingly, different
35
36 from their female counterparts, male participants showed no such association
37
38 (OR=0.6 95% CI: 0.3 to 1.4 P-value=0.24). Also, female participants had a higher risk
39
40 of VF given adverse side-effects (aOR=2.7 P-value=0.03). Male participants with
41
42 missed doses in the month prior to the survey were at a higher risk of both VF
43
44 (aOR=2.8 95% CI: 1.1 to 7 P-value=0.03) and HIVDR (aOR=9.7 95% CI: 2.1 to 44.1
45
46 P-value<0.01) versus those without missed doses in the preceding month. Conversely,
47
48 missed doses in prior month was not significantly associated with VF or HIVDR for
49
50 women.
51
52
53
54
55
56
57
58
59
60

HIV Drug Resistance and Subtype (Table 4)

HIVDR identified in our study was consistent with the NFATP recommended ART regimen. All 27 participants detected with drug resistance had NNRTI mutations, 21 (77.8%) had NRTI mutations. The dominant subtype was CRF07_BC for both males (61.5%) and females (50%). All participants found with HIVDR had developed HIVDR towards NNRTI; 85.7% male participants and 69.2% female developed HIVDR toward NRTI; no Protease Inhibitor mutation was detected. There were no CRF08_BC subtypes detected in the study population.

Discussion

The 48-month risk of VF was 11.8% and HIVDR was 5.0%, which indicated relatively good treatment outcomes given meta-analysis suggested a 37-48 months HIVDR prevalence ranging from 6.4%-47.92% in China,⁹ similar to a study in China which estimated a one-year VF and HIVDR incidence in 2009 of 3.5%.²⁵ Our study substantiates the finding that VF and HIVDR largely decreased since the wide-spread of 3TC-based regimens.²⁶ Studies have shown mixed findings of gender differences on ART adherence and treatment outcomes.^{14 16 27 28} In our study, we found male participants had slightly higher risk of VF (12.2% versus 11.2%, P-value = 0.72) but lower risk of HIVDR (2.4% versus 5.4%, P-value= 0.69) than women. Women's risks of VF and HIVDR were not associated with missing doses in the past month, and few

1
2
3
4 women missed doses relative to men, similar to two other studies in China suggesting
5
6 women have better adherence behaviors.^{29 30}
7

8
9 We found in this study that women, not men, who initiated D4T-based regimens were
10
11 more susceptible to VF (women vs. men OR=2.3 95% CI: 1.0 to 5.7 P-value= 0.06)
12
13 and HIVDR (women vs. men OR=3.0 95% CI: 0.8 to 11.3 P-value=0.11), consistent
14
15 with previous findings that D4T was more likely to increase the risk of mitochondrial
16
17 toxicity in women.^{31 32} Mitochondrial toxicity caused by D4T had been reported to
18
19 cause many adverse effects such as lactic acidosis, lipodystrophy, and peripheral
20
21 neuropathy.^{33 34} Following the WHO recommendation,³⁵ the NFATP advocated
22
23 switching the first-line regimen from D4T to TDF in 2012. The percentage of people
24
25 living with HIV initiating D4T-based regimen changed from 34.3% in 2010 to 10% in
26
27 2012 and 0.9% in 2014;³⁶ however, there were still 29.9% participants in our study
28
29 who were on D4T-based regimens in 2012. It was noteworthy that we did not see a
30
31 statistical difference in VF (OR=1.4 95% CI: 0.4 to 4.2 P-value=0.60) and HIVDR
32
33 (OR=1.0 95% CI: 0.2 to 4.2 P-value=0.98) between women who initiated and
34
35 remained on D4T-based regimens and those who switched to AZT/TDF based
36
37 regimens. It is a possible that women switched regimens because of VF; however,
38
39 further studies need to be done to explore when to switch ART regimen for women
40
41 receiving D4T-based regimens. It is important to mention that data on ART adherence
42
43 and adverse effects were collected in 2012, when there were only four female
44
45 participants still using D4T-based regimens who experienced VF. The sample size
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 was not sufficient enough to explore whether D4T-based regimens affect drug
5
6 adherence and adverse effects for women.
7

8
9 Drug adherence and adverse effects influenced our outcomes differently for men
10
11 compared to women. Male participants were at higher risk of both VF and HIVDR if
12
13 they reported missed doses. More detailed studies need to be conducted on the
14
15 frequency and factors associated with missing treatment. However, female
16
17 participants showed a higher risk of VF if they had adverse effect while men did not.
18
19 This calls for further researches of what types of adverse effects are occurring and
20
21 how they affect ART adherence and virological outcomes across gender.
22
23
24
25
26

27
28 Though not associated with the VF and HIVDR outcomes, 38.4% of study
29
30 participants reported that they would not 'always' be willing to take ART in the future,
31
32 36.8% reported not believing that ART is 'always' health promoting, and 42.5%
33
34 reported not believing that poor compliance 'always' contributed to HIVDR. As
35
36 willingness and these knowledge factors may impact more long-term VF and HIVDR
37
38 outcomes, the motivations behind willingness and knowledge about VF and HIVDR
39
40 warrant exploration.
41
42
43
44

45
46 Caution is needed when interpreting the study results from multivariate model that
47
48 older age (>45) was protective for HIVDR in men. There were only 4 male IDU
49
50 participants with older age (>45) in this study, the amount is not sufficient for us to
51
52 test for interaction. There is no association between HIVDR and age (OR=6.5 95% CI:
53
54 1.1 to 38.1 P-value=0.49) in the sub-analysis we did among participants with age ≤45,
55
56
57
58
59
60

1
2
3
4 after controlling for variables showed significant in the univariate model. A previous
5
6 study in HIV positive IDU population in China suggested that there is no association
7
8 between VF and sex or age.³⁷ In our study, 61.5% of male participants with HIVDR
9
10 became HIV infected via IDU, yet there were only 22.7% male IDU participants.
11

12
13
14 In addition, we found that younger (<45 years) IDU population were more likely to
15
16 miss doses (18.6%) compared to heterosexual transmission population (8.8%) and
17
18 blood transfusion transmission population (12.1%). This finding was consistent with
19
20 studies that implied younger males were at a higher risk of drug abuse.^{38 39} This result
21
22 indicated that younger IDU population could be a main source of VF and HIVDR;
23
24 therefore they could be future targeted population for behavioral intervention.
25
26

27
28
29 The increased risk of VF and HIVDR in non-Han minorities, regardless of gender,
30
31 may be due to logistical, cultural, or social barriers faced by ethnic minorities which
32
33 limit their adherence to ART. It has been reported that minorities tend to have lower
34
35 social economic status than Han majorities, followed by lower education level and
36
37 fewer access to health facilities.⁴⁰ It may be difficult for health professionals to reach
38
39 for some minorities because of their more remote geographic locations. Additionally,
40
41 several studies have reported that the percentage of high-risk populations such as
42
43 female sex workers (FSWs) and IDUs were higher in minorities than in Han majority.
44
45

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
41-43 The causes of this increased VF and HIVDR risk warrants further exploration,
and ethnic minorities may be an important group to tailor adherence-focused
interventions in China. The finding that higher CD4 cell count at follow-up was

1
2
3
4 protective for VF and HIVDR was expected. NFATP changed treatment criteria from
5
6 CD4 cell count ≤ 200 cells/mm³ to CD4 cell count ≤ 350 cells/mm³ following the WHO
7
8 recommendation in 2011,^{7 17 44}. Our study indicated that male participants who
9
10 initiated treatment in 2008 at CD4 cell count ≥ 350 cells/mm³ were still at higher risk
11
12 towards VF (aOR=7.1 95% CI: 1.1 to 45.8 P-value=0.04), supporting possible clinical
13
14 benefits of initiating ART at higher CD4 cell counts, < 500 cells/mm³ as per WHO
15
16 recommendation in 2013.⁴⁵

17
18 Among participants infected by blood transmission, we only found HIVDR subtype B;
19
20 only one subtype C was found in participants infected with IDU, the dominant
21
22 subtype was CRF07_BC, found both in participants infected by heterosexual
23
24 transmission and IDU. The most common NNRTI mutation sites were K103N
25
26 (40.7%), K101E (22.2%) and V108I (22.2%); the most common NRTI mutation sites
27
28 were M184V (81.0 %) and K70R (19%). Interestingly, compared to a one-year
29
30 follow-up study in China with all participants initiated ART in 2011,⁴⁶ there is no
31
32 V108I in their study and we did not find K65R in our study.

33
34 Study findings should be interpreted in light of several limitations. Though we did not
35
36 account for transmitted drug resistance in this study, previous studies have found low
37
38 transmitted drug resistance risk ($< 5\%$) during this period⁴⁷⁻⁴⁹ in China and we could
39
40 be fairly certain that participants were outcome free in 2008 as they were new ART
41
42 initiators. Another limitation of our study is that the outcomes were measured in 2011
43
44 and 2012, and thus we may be missing transient VF outcomes. Also, route of
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 transmission was collected in 2008 when assessing HIV infection among men who
5
6 have sex with men was not part of data collection instruments; additionally we do not
7
8 have data on sex worker status. Roughly half of the study participants selected for
9
10 possible inclusion in the study for having initiated first-line ART in 2008 were lost to
11
12 follow-up by 2012, creating a possible selection bias for individuals with better ART
13
14 adherence – this bias may underestimate the true VF and HIVDR risk and also limit
15
16 the generalizability of our findings to better adherers. Additionally, given the
17
18 demographic profile of the cohort, our findings are most generalizable to heterosexual
19
20 Han national who are married/cohabiting and working as agricultural labors in rural
21
22 areas. Misclassification of self-reported data is possible, though we do not expect this
23
24 misclassification to be differential by the outcome of interest and thus any such
25
26 information bias would bias our results toward the null.
27
28
29
30
31
32
33
34
35
36
37

38 **Conclusions**

39
40 We found female participants initiating D4T versus AZT-based regimens were more
41
42 vulnerable to VF and HIVDR, and we suggest future studies on whether and when to
43
44 change ART regimen for women initiated with D4T-based regimen. Poor adherence
45
46 was a risk factor among male participants who may benefit from reinforced adherence
47
48 counseling or social support. Increased VF and HIVDR risk among non-Han
49
50 minorities warrants further exploration, and ethnic minorities may be an important
51
52 group to tailor adherence-focused interventions in China. Finally, this study indicated
53
54
55
56
57
58
59
60

1
2
3
4 that younger men who become infected through IDU may be groups to strategically
5
6 focus counseling and increased adherence support programs.
7
8
9

10 11 **Funding**

12
13
14 This study was supported by Guangxi Center for Disease Control and Prevention,
15
16 Nanning, China. The antiretroviral drugs used in this study were provided by NFATP.
17
18

19 **Contributions:**

20
21 YR, WK, HX and YS designed the study. YR, HX, SL, LL, YM, HT, TZ, GS, HC,
22
23 WK, XL and PL collected the data. HC, TT and LL conducted laboratory analysis.
24
25 XL, WK analyzed the data. KW, VM, YR, WK, HX, LL and YS interpreted the data.
26
27
28 KW, VM, YR, WK, TT, and YS drafted the report. All authors reviewed, revised, and
29
30 approved the final report.
31
32
33
34
35
36

37 **Conflicts of interest:**

38 All authors declare that they have no conflicts of interest.
39
40
41
42
43
44
45

46 **Transparency declarations**

47
48 Vincent C. Marconi has received fees from ViiV Healthcare.
49
50
51
52
53
54
55
56
57
58
59
60


Figure 1. Figure of exclusion on study cohort

Table 1. Factors associated with virological failure (viral load ≥ 1000 copies/ml) stratified by sex

Demographic factors								
	Female				Male			
	Total	Virological failure Risk, N (%)	OR (95%CI)	P-value	Total	Virological failure Risk, N (%)	OR (95%CI)	P-value
Total	258	29 (11.2)			278	34 (12.2)		
Ethnicity								
Han nationality	191	19 (9.9)	1		219	20 (9.1)	1	
Other minorities	67	10 (14.9)	1.6 (0.7,3.6)	0.27	59	14 (23.7)	3.1 (1.5,6.6)	<0.01
Education								
Elementary school or less	134	15 (11.2)	1		107	12 (11.2)	1	
Junior school or more	124	14 (11.3)	1 (0.5,2.2)	0.98	171	22 (12.9)	1.2 (0.6,2.5)	0.68
Marital Status								
Single	59	6 (10.2)	1		75	9 (12)	1	
Married or Cohabited	199	23 (11.6)	1.2 (0.4,3.0)	0.77	203	25 (12.3)	1 (0.5,2.3)	0.94
Residence								
Rural	197	19 (9.6)	1		172	17 (9.9)	1	
City	61	10 (16.4)	1.8 (0.8,4.2)	0.15	106	17 (16)	1.7 (0.8,3.6)	0.13
Occupation								
Peasant	163	15 (9.2)	1		138	9 (6.5)	1	
Employee	64	11 (17.2)	2 (0.9,4.7)	0.09	114	17 (14.9)	2.5 (1.1,5.9)	0.03
Unemployed	31	3 (9.7)	1.1 (0.3,3.9)	0.93	26	8 (30.8)	6.4 (2.2,18.6)	<0.01
Age								
<35	73	6 (8.2)	1		53	7 (13.2)	1	

35-45	108	15 (13.9)	1.8 (0.7,4.9)	0.25	119	15 (12.6)	0.9 (0.4,2.5)	0.91
>45	77	8 (10.4)	1.3 (0.4,3.9)	0.65	106	12 (11.3)	0.8 (0.3,2.3)	0.73
Weight (kg)								
<50	89	14 (15.7)	1		49	7 (14.3)	1	
50-70	156	13 (8.3)	0.5 (0.2,1.1)	0.08	193	21 (10.9)	0.7 (0.3,1.8)	0.51
>70	13	2 (15.4)	1 (0.2,4.9)	0.97	36	6 (16.7)	1.2 (0.4,3.9)	0.76
HIV characteristics and treatment factors								
Route of Infection								
Heterosexual Transmission	159	12 (7.5)	1		154	11 (7.1)	1	
Blood Transmission	86	13 (15.1)	2.2 (0.9,5)	0.07	61	10 (16.4)	2.5 (1,6.4)	0.04
Intravenous Drug use	13	4 (30.8)	5.4 (1.5,20.3)	0.01	63	13 (20.6)	3.4 (1.4,8)	0.01
Initial NRTI ART regimen								
AZT based regimen	161	11 (6.8)	1		188	26 (13.8)	1	
D4T based regimen	97	18 (18.6)	3.1 (1.4,6.9)	<0.01	90	8 (8.9)	0.6 (0.3,1.4)	0.24
Latest NRTI ART regimen								
AZT based regimen	181	15 (8.3)	1		195	27 (13.8)	1	
D4T based regimen	77	14 (18.2)	2.5 (1.1,5.4)	0.02	83	7 (8.4)	0.6 (0.2,1.4)	0.21
Switch ART regimen								
No	193	21 (10.9)	1		174	21 (12.1)	1	
Yes	65	8 (12.3)	1.2 (0.5,2.7)	0.75	104	13 (12.5)	1 (0.5,2.2)	0.92
ART drug distribution location								
County hospital or CDC	96	15 (15.6)	1		63	14 (22.2)	1	
Township hospital /village clinic /medication monitor	162	14 (8.6)	0.5 (0.2,1.1)	0.09	215	20 (9.3)	0.4 (0.2,0.8)	0.01
Adverse effects								

No	195	17 (8.7)	1		206	23 (11.2)	1	
Yes	63	12 (19)	2.5 (1.1,5.5)	0.03	72	11 (15.3)	1.4 (0.7,3.1)	0.36
CD4 cell/ml at baseline (2008)								
<350	244	28 (11.5)	1		272	31 (11.4)	1	
≥350	14	1 (7.1)	0.6 (0.1,4.7)	0.62	6	3 (50)	7.8 (1.5,40.2)	0.01
CD4 cell/ml at 36 months (2011)								
0-350	91	18 (19.8)	1		138	21 (15.2)	1	
≥350	167	11 (6.6)	0.3 (0.1,0.6)	<0.01	140	13 (9.3)	0.6 (0.3,1.2)	0.13
CD4 cell/ml at 48 months (2012)								
0-350	81	14 (17.3)	1		122	20 (16.4)	1	
≥350	177	15 (8.5)	0.4 (0.2,1)	0.04	156	14 (9)	0.5 (0.2,1)	0.06
Drug compliance factors								
Missed doses in past month								
No	226	26 (11.5)	1		246	24 (9.8)	1	
Yes	32	3 (9.4)	0.8 (0.2,2.8)	0.72	32	10 (31.3)	4.2 (1.8,9.9)	<0.01
Willing to receive ART in the future								
Always	153	15 (9.8)	1		177	19 (10.7)	1	
Not always	105	14 (13.3)	1.4 (0.7,3.1)	0.38	101	15 (14.9)	1.5 (0.7,3)	0.32
Believe ART is health promoting								
Always	158	16 (10.1)	1		181	19 (10.5)	1	
Not always	100	13 (13)	1.3 (0.6,2.9)	0.48	97	15 (15.5)	1.6 (0.8,3.2)	0.24
Believe poor compliance contribute to HIVDR								
Always	139	16 (11.5)	1		169	19 (11.2)	1	
Not always	119	13 (10.9)	0.9 (0.4,2.1)	0.88	109	15 (13.8)	1.3 (0.6,2.6)	0.53

Degree of satisfaction on support of friends or relatives								
Always satisfied	153	15 (9.8)	1		166	17 (10.2)	1	
Not always satisfied	105	14 (13.3)	1.4 (0.7,3.1)	0.38	112	17 (15.2)	1.6 (0.8,3.2)	0.22
Frequency of taking drugs reminded by friends or relatives								
Often	172	19 (11)	1		168	22 (13.1)	1	
Not often	86	10 (11.6)	1.4 (0.7,3.1)	0.38	110	12 (10.9)	0.8 (0.4,1.7)	0.58
Frequency of taking drugs reminded by doctors								
Often	178	23 (12.9)	1		184	28 (15.2)	1	
Not often	80	6 (7.5)	0.5 (0.2,1.4)	0.19	94	6 (6.4)	0.4 (0.2,1)	0.03

*OR: odds ratio; CI: confidence interval; HIVDR: HIV drug resistance; ART: antiretroviral treatment; AZT: Zidovudine; D4T: Stavudine

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2. Factors associated with HIVDR (viral load ≥ 1000 copies/ml with drug resistance) stratified by sex

Demographic factors								
	Female				Male			
	Total	HIVDR Risk N (%)	OR (95%CI)	P-value	Total	HIVDR Risk N (%)	OR (95%CI)	P-value
Total	258	14 (5.4)			278	13 (2.4)		
Ethnicity								
Han nationality	191	6 (3.1)	1		219	5 (1.2)	1	
Other minorities	67	8 (11.9)	4.2 (1.4 to 12.5)	0.01	59	8 (6.3)	6.7 (2.1 to 21.4)	<0.01
Education								
Elementary school or less	134	5 (3.7)	1		107	5 (2.1)	1	
Junior school or more	124	9 (7.3)	2 (0.7 to 6.2)	0.22	171	8 (2.7)	1 (0.3 to 3.1)	1
Marital Status								
Single	59	4 (6.8)	1		75	4 (3)	1	
Married or Cohabited	199	10 (5)	0.7 (0.2 to 2.4)	0.60	203	9 (2.2)	0.8 (0.2 to 2.8)	0.75
Residence								
Rural	197	7 (3.6)	1		172	5 (1.4)	1	
City	61	7 (11.5)	3.5 (1.2 to 10.5)	0.02	106	8 (4.8)	2.7 (0.9 to 8.6)	0.09
Occupation								
Peasant	163	5 (3.1)	1		138	0	1	
Employee	64	6 (9.4)	3.3 (1 to 11.1)	0.06	114	9 (5.1)	2 (1 to 12.6)	<0.01
Unemployed	31	3 (9.7)	3.4 (0.8 to 15)	0.11	26	4 (7)	3 (1 to 13.4)	<0.01
Age								
<35	73	5 (6.8)	1		53	6 (4.8)	1	
35-45	108	6 (5.6)	0.8 (0.2 to 2.7)	0.72	119	6 (2.6)	0.4 (0.1 to 1.4)	0.15

>45	77	3 (3.9)	0.6 (0.1 to 2.4)	0.43	106	1 (0.5)	0.1 (0 to 0.6)	0.02
Weight (kg)								
<50	89	8 (9)	1		49	4 (2.9)	1	
50-70	156	4 (2.6)	0.3 (0.1 to 0.9)	0.04	193	7 (2)	0.4 (0.1 to 1.5)	0.19
>70	13	2 (15.4)	1.8 (0.3 to 9.8)	0.47	36	2 (4.1)	0.7 (0.1 to 3.8)	0.64
HIV characteristics and treatment factors								
Route of Infection								
Heterosexual Transmission	159	8 (5)	1		154	2 (0.6)	1	
Blood Transmission	86	4 (4.7)	0.9 (0.3 to 3.2)	0.9	61	3 (2)	3.9 (0.6 to 24.1)	0.14
Intravenous Drug use	13	2 (15.4)	3.4 (0.6 to 18.2)	0.15	63	8 (10.5)	11.1 (2.3 to 53.7)	<0.01
Initial NRTI ART regimen								
AZT based regimen	161	5 (3.1)	1		188	10 (2.9)	1	
bvg based regimen	97	9 (9.3)	3.2 (1 to 9.8)	0.04	90	3 (1.6)	0.6 (0.2 to 2.3)	0.47
Latest ART regimen								
AZT based regimen	181	8 (4.4)	1		195	12 (3.2)	1	
D4T based regimen	77	6 (7.8)	1.8 (0.6 to 5.5)	0.28	83	1 (0.6)	0.2 (0 to 1.5)	0.11
Switch ART regimen								
No	193	10 (5.2)	1		174	6 (1.6)	1	
Yes	65	4 (6.2)	1.2 (0.4 to 4)	0.76	104	7 (4.1)	2 (0.7 to 6.2)	0.22
Adverse side-effect								
No	195	9 (4.6)	1		206	10 (2.5)	1	
Yes	63	5 (7.9)	1.8 (0.6 to 5.5)	0.32	72	3 (2.2)	0.9 (0.2 to 3.2)	0.81
CD4 cell at baseline (2008)								
<350	244	14 (5.7)			272	12 (2.3)	1	
≥350	14	0	-	0.36	6	1 (5)	4.3 (0.5 to 40)	0.2
CD4 cell at 36 months (2011)								

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

0-350	91	9 (9.9)	1		138	11 (4.8)	1	
≥350	167	5 (3)	0.3 (0.1 to 0.9)	0.03	140	2 (0.7)	0.2 (0 to 0.8)	0.02
CD4 cell at 48 months (2012)								
0-350	81	7 (8.6)	1		122	11 (5.4)	1	
≥350	177	7 (4)	0.4 (0.1 to 1.3)	0.13	156	2 (0.6)	0.1 (0 to 0.6)	0.01
Drug compliance factors								
Missed doses in past month								
No	226	13 (5.8)	1		246	6 (1.3)	1	
Yes	32	1 (3.1)	0.5 (0.1 to 4.2)	0.55	32	7 (10.9)	11.2 (3.5 to 35.9)	<0.01

* ART drug distribution location, Willing to receive ART in the future, Believe ART is health promoting, Believe poor compliance contribute to HIVDR, Degree of satisfaction on support of friends or relatives, Frequency of taking drugs reminded by friends or relatives, Frequency of taking drugs reminded by doctors are not displayed for no statistical significant difference between categorizes.

* OR: odds ratio; CI: confidence interval; HIVDR: HIV drug resistance; ART: antiretroviral treatment; AZT: Zidovudine; D4T: Stavudine

Table 3. Multivariate Models of Factors associated with virological failure (viral load ≥ 1000 copies/ml) and HIVDR (viral load ≥ 1000 copies/ml with drug resistance) stratified by sex

Variables	Female				Male			
	Virological failure		HIVDR		Virological failure		HIVDR	
	Adjusted OR (95%CI)	P-value	Adjusted OR (95%CI)	P-value	Adjusted OR (95%CI)	P-value	Adjusted OR (95%CI)	P-value
Total								
Ethnicity								
Han nationality			1		1		1	
Other minorities			4.8 (1.2 to 19.7)	0.03	2.9 (1.1 to 7.3)	0.02	12.2 (1.8 to 84.8)	0.01
Residence								
Rural			1					
City			2.4 (0.6 to 9.5)	0.22				
Age								
<35							1	
35-45							0.3 (0.1 to 1.4)	0.12
>45							0.03 (0 to 0.6)	0.02
Weight (kg)								
<50			1					
50-70			0.3 (0.1 to 1.1)	0.08				
>70			4.2 (0.6 to 30.0)	0.15				
Route of Infection								
Heterosexual Transmission	1				1		1	
Blood Transmission	1.2 (0.5 to 3)	0.74			1.8 (0.6 to 5.8)	0.33	7 (0.8 to 64.4)	0.09
Intravenous Drug use	4.1 (1 to 17.7)	0.06			2.1 (0.8 to 5.4)	0.12	2.3 (0.3 to 16.1)	0.41
Initial NRTI ART regimen								

AZT based regimen	1		1					
D4T based regimen	2.5 (1 to 6.1)	0.04	3.6 (1 to 12.6)	0.05				
ART drug distribution location								
County hospital or CDC					1			
Township hospital /village clinic /medication monitor					0.5 (0.2 to 1.3)	0.18		
Adverse effect								
No	1							
Yes	2.3 (1 to 5.6)	0.06						
CD4 cell at baseline (2008)								
<350					1			
≥350					7.1 (1.1 to 45.8)	0.04		
CD4 cell at 36 months (2011)								
<350	1		1				1	
≥350	0.4 (0.2 to 1.1)	0.07	0.3 (0.1 to 0.9)	0.04			0.3 (0 to 1.9)	0.2
CD4 cell at 48 months (2012)								
<350	1						1	
≥350	0.6 (0.3 to 1.6)	0.36					0.1 (0 to 1)	0.05
Missed doses in past month								
No					1		1	
Yes					2.8 (1.1 to 7)	0.03	9.7 (2.1 to 44.1)	<0.01
Frequency of taking drugs reminded by doctors								
Often					1			
Not often					0.4 (0.2 to 1.2)	0.12		

* OR: odds ratio; CI: confidence interval; HIVDR: HIV drug resistance; ART: antiretroviral treatment; AZT: Zidovudine; D4T: Stavudine

Table 4. HIV Drug Resistance and Subtype among 27 patients with HIVDR Mutation Detected at 2011 and/or 2012 stratified by sex

	Female (%)	Male (%)	Mutations	N (%)
Overall	14	13		
Subtype				
B	5 (35.7)	3 (23.1)		
C		1 (7.7)		
CRF01_AE	2 (14.3)	1 (7.7)		
CRF07_BC	7 (50)	8 (61.5)		
Antiretroviral Drug				
Non-nucleoside reverse transcriptase inhibitors (NNRTI,any)	14 (100)	13 (100)	NNRTI Mutations(total)	27
Efavirenz (EFV)	14 (100)	13 (100)	V90I	1 (3.7)
Nevirapine (NVP)	14 (100)	13 (100)	A98G	2 (7.4)
Etravirine (ETR)	6 (42.9)	8 (61.5)	K101E	6 (22.2)
			K103N	11 (40.7)
			V106A	4 (14.8)
			V108I	6 (22.2)
			E138A	1 (3.7)
			V179D/F	3 (11.1)
			Y181C	5 (18.5)
			G190A	5 (18.5)
			H221Y	1 (3.7)
			P225H	3 (11.1)
			F227L	1 (3.7)
			M230L	1 (3.7)

Nucleoside reverse transcriptase inhibitors (NRTI,any)	12 (85.7)	9 (69.2)	NRTI Mutations(total)	21
Lamivudine (3TC)	12 (85.7)	9 (69.2)	A62V	1 (4.8)
Azidothymidine (AZT)	2 (14.3)	2 (15.4)	D67G	1 (4.8)
Tenofovir (TDF)	1 (7.1)	3 (23.1)	T69N	2 (9.5)
Stavudine (D4T)	3 (21.4)	3 (23.1)	K70R/Q	4 (19)
Didanosine (DDI)	5 (35.7)	3 (23.1)	V75I/M	2 (9.5)
Abcavir (ABC)	12 (85.7)	9 (69.2)	M184V	17 (81.0)
Emtricitabine (FTC)	12 (85.7)	9 (69.2)	T215N	1 (4.8)
			K219E/Q	2 (9.5)
Protease inhibitors (PI,any)	0	0	PI Mutations(total)	0

*NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitors; NRTI: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors; PI: Protease Inhibitor

- 1
2
3 1. Hong SY, Nachega JB, Kelley K, et al. The global status of HIV drug resistance:
4 clinical and public-health approaches for detection, treatment and prevention.
5 *Infectious disorders drug targets* 2011;11(2):124-33.
- 6
7 2. Gabillard D, Lewden C, Ndoye I, et al. Mortality, AIDS-morbidity, and loss to
8 follow-up by current CD4 cell count among HIV-1-infected adults receiving
9 antiretroviral therapy in Africa and Asia: data from the ANRS 12222
10 collaboration. *Journal of acquired immune deficiency syndromes*
11 2013;62(5):555-61. doi: 10.1097/QAI.0b013e3182821821
- 12
13 3. Montaner JS, Lima VD, Harrigan PR, et al. Expansion of HAART coverage is
14 associated with sustained decreases in HIV/AIDS morbidity, mortality and
15 HIV transmission: the "HIV Treatment as Prevention" experience in a
16 Canadian setting. *PloS one* 2014;9(2):e87872. doi:
17 10.1371/journal.pone.0087872
- 18
19 4. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine
20 and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and
21 lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. *The*
22 *New England journal of medicine* 1999;341(25):1865-73. doi:
23 10.1056/NEJM199912163412501
- 24
25 5. Wang X, Yang L, Li H, et al. Factors associated with HIV virologic failure among
26 patients on HAART for one year at three sentinel surveillance sites in China.
27 *Current HIV research* 2011;9(2):103-11.
- 28
29 6. Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China National Free
30 Antiretroviral Treatment Program. *Annals of internal medicine*
31 2009;151(4):241-51, W-52.
- 32
33 7. Chinese Center of Disease and Control. Manual of the National Free Antiretroviral
34 Treatment, 2007 edition 2007
- 35
36 8. People's Republic of China (2008) UNGASS Country Progress Report. *Beijing:*
37 *People's Republic of China* 2007
- 38
39 9. Liu H, Ma Y, Su Y, et al. Emerging trends of HIV drug resistance in Chinese HIV-
40 infected patients receiving first-line highly active antiretroviral therapy: a
41 systematic review and meta-analysis. *Clinical infectious diseases : an official*
42 *publication of the Infectious Diseases Society of America* 2014;59(10):1495-
43 502. doi: 10.1093/cid/ciu590
- 44
45 10. Djarma O, Nguyen Y, Renois F, et al. Continuous free access to HAART could be
46 one of the potential factors impacting on loss to follow-up in HAART-eligible
47 patients living in a resource-limited setting: N'djamena, Chad. *Transactions of*
48 *the Royal Society of Tropical Medicine and Hygiene* 2014;108(11):735-8. doi:
49 10.1093/trstmh/tru130
- 50
51 11. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug
52 resistance and response to antiretroviral therapy: re-analysis of retrospective
53 and prospective studies using a standardized data analysis plan. *Antiviral*
54 *therapy* 2000;5(1):41-8.
- 55
56
57
58
59
60

12. Liao L, Xing H, Su B, et al. Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China. *Aids* 2013;27(11):1815-24. doi: 10.1097/QAD.0b013e3283611931
13. Hare AQ, Ordonez CE, Johnson BA, et al. Gender-specific risk factors for virologic failure in KwaZulu-Natal: automobile ownership and financial insecurity. *AIDS and behavior* 2014;18(11):2219-29. doi: 10.1007/s10461-014-0849-1
14. Berg KM, Demas PA, Howard AA, et al. Gender differences in factors associated with adherence to antiretroviral therapy. *Journal of general internal medicine* 2004;19(11):1111-7. doi: 10.1111/j.1525-1497.2004.30445.x
15. Floridia M, Giuliano M, Palmisano L, et al. Gender differences in the treatment of HIV infection. *Pharmacological research* 2008;58(3-4):173-82. doi: 10.1016/j.phrs.2008.07.007
16. Moore AL, Mocroft A, Madge S, et al. Gender differences in virologic response to treatment in an HIV-positive population: a cohort study. *Journal of acquired immune deficiency syndromes* 2001;26(2):159-63.
17. World Health Organization. Surveillance Of HIV Drug Resistance In Adults Receiving Art (Acquired Hiv Drug Resistance). Accessed July 2014. 2014
18. Bennett DE, Myatt M, Bertagnolio S, et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. *Antiviral therapy* 2008;13 Suppl 2:25-36.
19. Gaydos CA, Rizzo-Price PA, Balakrishnan P, et al. Impact of international laboratory partnerships on the performance of HIV/sexually transmitted infection testing in five resource-constrained countries. *International journal of STD & AIDS* 2011;22(11):645-52. doi: 10.1258/ijsa.2011.010527
20. Organization WH. World Health Organization Protocol for Population Based Monitoring of HIV Drug Resistance Emerging During Treatment and Related Program Factors at Sentinel Antiretroviral Therapy Clinics.
21. Jiang Y, Qiu M, Zhang G, et al. Quality assurance in the HIV/AIDS laboratory network of China. *International journal of epidemiology* 2010;39 Suppl 2:ii72-8. doi: 10.1093/ije/dyq224
22. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2006;42(11):1608-18. doi: 10.1086/503914
23. Yan H, Yu H, Xing W, et al. Development of a proficiency testing program for the HIV-1 BED incidence assay in China. *Scientific reports* 2014;4:4512. doi: 10.1038/srep04512
24. Zhong P, Pan Q, Ning Z, et al. Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. *AIDS*

- 1
2
3 *research and human retroviruses* 2007;23(7):847-56. doi:
4 10.1089/aid.2006.0196
- 5
6 25. Xing H, Wang X, Liao L, et al. Incidence and associated factors of HIV drug
7 resistance in Chinese HIV-infected patients receiving antiretroviral treatment.
8 *PloS one* 2013;8(4):e62408. doi: 10.1371/journal.pone.0062408
- 9
10 26. Xing H, Ruan Y, Hsi JH, et al. Reductions in virological failure and drug
11 resistance in Chinese antiretroviral-treated patients due to lamivudine-based
12 regimens, 2003–12. *Journal of Antimicrobial Chemotherapy* 2015:dkv078.
- 13
14 27. Nicastrì E, Leone S, Angeletti C, et al. Sex issues in HIV-1-infected persons
15 during highly active antiretroviral therapy: a systematic review. *The Journal of*
16 *antimicrobial chemotherapy* 2007;60(4):724-32. doi: 10.1093/jac/dkm302
- 17
18 28. Puskas CM, Forrest JI, Parashar S, et al. Women and vulnerability to HAART
19 non-adherence: a literature review of treatment adherence by gender from
20 2000 to 2011. *Current HIV/AIDS reports* 2011;8(4):277-87. doi:
21 10.1007/s11904-011-0098-0
- 22
23 29. Dou Z, Xu J, Jiao JH, et al. Gender difference in 2-year mortality and
24 immunological response to ART in an HIV-infected Chinese population,
25 2006–2008. *PloS one* 2011;6(8):e22707. doi: 10.1371/journal.pone.0022707
- 26
27 30. Sabin LL, Desilva MB, Hamer DH, et al. Barriers to adherence to antiretroviral
28 medications among patients living with HIV in southern China: a qualitative
29 study. *AIDS care* 2008;20(10):1242-50. doi: 10.1080/09540120801918651
- 30
31 31. Wester CW, Okezie OA, Thomas AM, et al. Higher-than-expected rates of lactic
32 acidosis among highly active antiretroviral therapy-treated women in
33 Botswana: preliminary results from a large randomized clinical trial. *Journal*
34 *of acquired immune deficiency syndromes* 2007;46(3):318-22. doi:
35 10.1097/QAI.0b013e3181568e3f
- 36
37 32. Goedecke JH, Micklesfield LK, Levitt NS, et al. Effect of different antiretroviral
38 drug regimens on body fat distribution of HIV-infected South African women.
39 *AIDS research and human retroviruses* 2013;29(3):557-63. doi:
40 10.1089/aid.2012.0252
- 41
42 33. Feleke Y, Fekade D, Mezegebu Y. Prevalence of highly active antiretroviral
43 therapy associated metabolic abnormalities and lipodystrophy in HIV infected
44 patients. *Ethiopian medical journal* 2012;50(3):221-30.
- 45
46 34. Moyle GJ, Nelson MR, Hawkins D, et al. The use and toxicity of didanosine (ddI)
47 in HIV antibody-positive individuals intolerant to zidovudine (AZT). *The*
48 *Quarterly journal of medicine* 1993;86(3):155-63.
- 49
50 35. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and
51 Preventing HIV Infection: Recommendations for a Public Health Approach.
52 Geneva2013.
- 53
54 36. Dou Z, Zhang F, Zhao Y, et al. Progress on China's national free antiretroviral
55 therapy strategy in 2002-2014. *Chinese Journal Epidemiology*
56 2015;36(12):1345-50.
- 57
58
59
60

- 1
2
3 37. Leng X, Liang S, Ma Y, et al. HIV virological failure and drug resistance among
4 injecting drug users receiving first-line ART in China. *BMJ open*
5 2014;4(10):e005886.
6
7 38. Wu Z, Zhang J, Detels R, et al. Characteristics of risk-taking behaviors, HIV and
8 AIDS knowledge, and risk perception among young males in southwest China.
9 *AIDS education and prevention : official publication of the International*
10 *Society for AIDS Education* 1997;9(2):147-60.
11
12 39. Yang H, Li X, Stanton B, et al. Heterosexual transmission of HIV in China: a
13 systematic review of behavioral studies in the past two decades. *Sexually*
14 *transmitted diseases* 2005;32(5):270-80.
15
16 40. Myers Jr SL, Xiaoyan G, Cruz BC. Ethnic minorities, race, and inequality in
17 China: A new perspective on racial dynamics. *Review of Black Political*
18 *Economy* 2013;40(3):231.
19
20 41. Zoufaly A, Jochum J, Hammerl R, et al. Virological failure after 1 year of first-
21 line ART is not associated with HIV minority drug resistance in rural
22 Cameroon. *The Journal of antimicrobial chemotherapy* 2015;70(3):922-5. doi:
23 10.1093/jac/dku470
24
25 42. Shou L, WANG QX, Lei N, et al. The changing trends of HIV/AIDS in an ethnic
26 minority region of China: modeling the epidemic in Liangshan prefecture,
27 Sichuan Province. *Biomedical and Environmental Sciences* 2013;26(7):562-70.
28
29 43. Zhang L, Zhu J, Rui B, et al. High HIV risk among Uigur minority ethnic drug
30 users in northwestern China. *Tropical Medicine & International Health*
31 2008;13(6):814-17.
32
33 44. Chinese Center for Disease Control and Prevention. Manual of the National Free
34 Antiretroviral Treatment, third edition. Accessed 2013 Jun 12. . 2013
35
36 45. World Health Organization. Consolidated guidelines on general HIV care and the
37 use of antiretroviral drugs for treating and preventing HIV infection:
38 recommendations for a public health approach: World Health Organization
39 2013.
40
41 46. Xing H, Ruan Y, Hsi JH, et al. Reductions in virological failure and drug
42 resistance in Chinese antiretroviral-treated patients due to lamivudine-based
43 regimens, 2003-12. *The Journal of antimicrobial chemotherapy*
44 2015;70(7):2097-103. doi: 10.1093/jac/dkv078
45
46 47. Liao L, Xing H, Shang H, et al. The prevalence of transmitted antiretroviral drug
47 resistance in treatment-naïve HIV-infected individuals in China. *Journal of*
48 *acquired immune deficiency syndromes* 2010;53 Suppl 1:S10-4. doi:
49 10.1097/QAI.0b013e3181c7d363
50
51 48. Zhao K, Kang W, Liu Q, et al. Genotypes and transmitted drug resistance among
52 treatment-naïve HIV-1-infected patients in a northwestern province, China:
53 trends from 2003 to 2013. *PloS one* 2014;9(10):e109821. doi:
54 10.1371/journal.pone.0109821
55
56
57
58
59
60

- 1
2
3 49. Su Y, Zhang F, Liu H, et al. The prevalence of HIV-1 drug resistance among
4 antiretroviral treatment naive individuals in mainland China: a meta-analysis.
5 *PloS one* 2014;9(10):e110652. doi: 10.1371/journal.pone.0110652
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Page	Recommendation
Title and abstract	1	2	(a) Indicate the study's design with a commonly used term in the title or the abstract
		2-3	(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction			
Background/rationale	2	5	Explain the scientific background and rationale for the investigation being reported
Objectives	3	6	State specific objectives, including any prespecified hypotheses
Methods			
Study design	4	7	Present key elements of study design early in the paper
Setting	5	7	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	7	(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
			<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls
			<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants
			<i>(b) Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed
			<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	8-9	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	9	Describe any efforts to address potential sources of bias
Study size	10	9	Explain how the study size was arrived at
Quantitative variables	11	9	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	9	(a) Describe all statistical methods, including those used to control for confounding
		9	(b) Describe any methods used to examine subgroups and interactions
		7,9-10	(c) Explain how missing data were addressed
		10	
		9-10	(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy
			(e) Describe any sensitivity analyses

Results

Participants	13*	9	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		9-10	(b) Give reasons for non-participation at each stage
		19	(c) Consider use of a flow diagram
Descriptive data	14*	10	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
			(b) Indicate number of participants with missing data for each variable of interest
		10	(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	10	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time
			<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure
			<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	11,9	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		8	(b) Report category boundaries when continuous variables were categorized
			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	14-15	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18	12	Summarise key results with reference to study objectives
Limitations	19	16	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	12-16	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	17	Discuss the generalisability (external validity) of the study results

Other information

Funding	22	18	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
---------	----	----	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Predictors of HIV Virologic Failure And Drug Resistance In Chinese Patients After 48 Months Of Antiretroviral Treatment, 2008-2012 : A Prospective Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016012.R1
Article Type:	Research
Date Submitted by the Author:	13-Jun-2017
Complete List of Authors:	<p>Kan, Wei; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China; Emory University School of Public Health, Department of Epidemiology</p> <p>Teng, Tao; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China</p> <p>Liang, Shujia; Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention</p> <p>Ma, Yanling; Yunnan Center for Disease Control and Prevention, Kunming, China,</p> <p>Tang, Heng; Hubei Center for Disease Control and Prevention</p> <p>Zuohela, Tuerdi; Xinjiang Uighur Autonomous Region Center for Disease Control and Prevention</p> <p>Sun, Guoqing; Henan Province Center for Disease Control and Prevention</p> <p>He, Cui; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China,</p> <p>Wall, Kristin; Emory University School of Public Health, Department of Epidemiology</p> <p>Marconi, Vincent; Emory University School of Public Health, Department of Global Health; Emory University School of Medicine, Division of Infectious</p> <p>Liao, Lingjie; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China,</p> <p>Leng, Xuebing; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China,</p> <p>Liu, Pengtao ; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China</p> <p>Ruan, Yuhua; Chinese Center for AIDS/STD Control and Prevention, Division of Virology and Immunology</p> <p>Xing, Hui; State Key Laboratory for Infectious Disease Prevention and</p>

	Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China, Shao, Yiming; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	Public health
Keywords:	Antiretroviral Treatment, Virological Failure, Drug Resistance, Gender Difference, HIV & AIDS < INFECTIOUS DISEASES>

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
60

1 **Predictors of HIV Virologic Failure And Drug Resistance In Chinese Patients**
2 **After 48 Months Of Antiretroviral Treatment, 2008-2012 : A Prospective**
3 **Corhort Study**

5 Wei Kan^{1,7*}, Tao Teng^{1*}, Shujia Liang², Yanling Ma³, Heng Tang⁴, Tuerdi Zuohela⁵,
6 Guoqing Sun⁶, Cui He¹, Kristin M. Wall⁷, Vincent C. Marconi^{8,9}, Lingjie Liao¹,
7 Xuebing Leng¹, Pengtao Liu¹, Yuhua Ruan¹, Hui Xing¹, Yiming Shao¹

- 8
9 1. State Key Laboratory for Infectious Disease Prevention and Control, National
10 Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control
11 and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of
12 Infectious Diseases, Beijing, China
13 2. Guangxi Center for Disease Control and Prevention, Nanning, China
14 3. Yunnan Center for Disease Control and Prevention, Kunming, China
15 4. Hubei Center for Disease Control and Prevention, Wuhan, China
16 5. Xinjiang Autonomous Region Center for Disease Control and Prevention,
17 Urumqi, China
18 6. Henan Center for Disease Control and Prevention, Zhengzhou, China
19 7. Department of Epidemiology, Rollins School of Public Health, Emory University,
20 Atlanta, Georgia.
21 8. Department of Global Health, Rollins School of Public Health, Emory University,
22 Atlanta, Georgia.
23 9. Division of Infectious Diseases, Emory University School of Medicine, Atlanta,
24 Georgia

25
26 *These authors contributed equally to this work

27 Running head: Virologic failure and drug resistance among HIV+ Chinese ART
28 patients

1 **Body: 3,111**

2 **ABSTRACT**

3 **Objective:** To explore factors associated with HIV virologic failure (VF) and HIV
4 drug resistance (HIVDR) among HIV-positive Chinese individuals four years after
5 initiating first-line 3TC-based antiretroviral treatment (ART) in 2008 at five sentinel
6 sites.

7 **Design:** First-line ART initiators who were previously treatment naïve were selected
8 using consecutive ID numbers from the 2008 National Surveillance Database into a
9 prospective cohort study. Questionnaires and Blood samples were collected in 2011
10 and 2012 to assess the outcomes of interest: VF (defined as viral load \geq 1000
11 copies/ml) and HIVDR (defined as VF with genetic drug resistant mutations).
12 Questionnaires and data from National Surveillance Database assessed demographics
13 and drug adherence data.

14 **Results:** 536 individuals with HIV were analyzed; the 4-year risk of VF was
15 63(11.8%) and HIVDR was 27(5.0%). Female participants initiating D4T-based
16 regimens were more susceptible to both VF (adjusted odds ratio, aOR=2.5, 95% CI:
17 1-6.1, P-value=0.04) and HIVDR (aOR=3.6, 95% CI: 1 to 12.6, P-value=0.05) versus
18 AZT-based regimens. Male participants missing doses in past month were more
19 susceptible to both VF (aOR=2.8, 95% CI: 1.1 to 7, P-value=0.03) and HIVDR
20 (aOR=9.7, 95% CI: 2.1 to 44.1, P-value<0.01). Participants of non-Han nationality
21 were of increased risk for HIVDR (aOR from 4.8-12.2, P-value<0.05) and non-Han

1 men were at increased risk for VF (aOR=2.9, 95% CI: 1.1 to .3, P-value=0.02). All 27
2 participants detected with HIVDR had non-nucleoside reverse-transcriptase inhibitor
3 (NNRTI) mutations, 21 (77.8%) also had NRTI mutations, and no protease inhibitor
4 mutations were detected.

5 **Conclusions:** Our findings suggest successful treatment outcomes at 4-years for
6 roughly 90% of patients. We suggest conducting further study on whether and when
7 to change ART regimen for women initiated with D4T-based regimen, and
8 reinforcing adherence counseling for men. Increased VF and HIVDR risk among non-
9 Han minorities warrants further exploration, and ethnic minorities may be an
10 important group to tailor adherence-focused interventions.

11 **Strengths and limitations of this study**

- 12 ▪ We studied 48-month risk of VF and HIVDR and their associations with
13 demographic and behavioral information among individuals across five
14 sentinel sites.
- 15 ▪ Study found drug adherence and adverse effects influenced VF and HIVDR
16 differently across gender..
- 17 ▪ The outcomes were measured in 2011 and 2012, and thus we may be missing
18 transient VF outcomes.

1
2
3 1 **Key words:** HIV, Antiretroviral Treatment, Virological Failure, Drug Resistance,
4 2 Gender Differences, China
5
6
7
8
9

4 **Corresponding author:**

5 Yiming Shao

6 State Key Laboratory for Infectious Disease Prevention and Control, and National
7 Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control
8 and Prevention, Beijing, China

9 No. 155 Changbai Road, Changping District, Beijing 102206, P. R. China

10 Telephone: + 86-10-58900647 Fax: +86-10-58900980

11 E-mail: yshao08@gmail.com
12
13

1 Introduction

2 Antiretroviral treatment (ART) has dramatically improved health outcomes and
3 decreased HIV-associated morbidity and mortality through virologic suppression and
4 subsequent CD4 recovery.¹⁻⁴ In 2003, China launched a National Free Antiretroviral
5 Treatment Program (NFATP) that includes life-long provision of free ART for people
6 living with HIV who met the national treatment criteria.^{5,6} The national treatment
7 criteria from 2008 to 2011 were: (1) CD4 cell count $\leq 200/\text{mm}^3$; (2) World Health
8 Organization (WHO) stage III/IV diseases; or (3) willingness to receive ART,
9 regardless of criteria 1 and 2.⁷

10 The State Council AIDS Working Committee Office and the United Nations Theme
11 Group on AIDS estimated that there were more than 700,000 persons living with HIV
12 in China in 2008, and more than 52,000 individuals with HIV across 31 provinces,
13 autonomous regions, and municipalities had received ART (made freely available by
14 the NFATP) by August 2008.⁸

15 With the rapid scale-up of treatment and challenges with adherence, virologic failure
16 (VF) and HIV drug resistance (HIVDR) are ever present and mounting concerns.

17 Incomplete virologic suppression, a major cause of HIVDR, not only compromises
18 therapeutic efficacy for the individual receiving treatment, increasing the risk of viral
19 rebound and opportunistic infections, but also increases the risk of transmitting drug
20 resistant strains to other individuals in the general population.^{9,10,11}

1
2
3
4 1 Observational studies in China have documented the prevalence of VF and HIVDR
5
6 2 strains among treated individuals living with HIV. A cross-sectional study conducted
7
8
9 3 in Yunnan, Guangxi and Xinjiang provinces in 2010 stated that one-year HIVDR
10
11 4 prevalence was 4.1%⁵. VF prevalence for sexual transmitted population and
12
13
14 5 intravenous drug users (IDUs) were 8.3% and 19.3%, separately. A 6-year follow-up
15
16
17 6 study in 2010 suggested an incidence of 14.1 per 100 person-year for VF and 11.9 per
18
19
20 7 100 person-year for HIVDR among former plasma donors in Anhui Province.¹²
21
22 8 NFATP recommended to switch the first-line regimen from Didanosine (DDI) to
23
24 9 Lamivudine (3TC) in 2008, and there are few nationwide, prospective studies in
25
26
27 10 China reporting frequency or predictors of VF and HIVDR for people after initiating
28
29
30 11 3TC based regimens.
31
32 12 The aim of this study is to evaluate predictors of VF and HIVDR in a prospective
33
34
35 13 cohort of Chinese HIV individuals with HIV four years after first initiating first-line
36
37
38 14 3TC-based ART in 2008 at five sentinel sites. We stratified our analyses by gender
39
40
41 15 based on conflicting findings on gender differences both in virological responses and
42
43
44 16 drug resistance to different ART regimen, as well as gender differences in ART
45
46
47 17 adherence.¹³⁻¹⁶ To our knowledge, this is the first long-term study to evaluate VF and
48
49
50 18 HIVDR on 3TC-based regimens.

19 **Ethics Statement**

20 The study was approved by the institutional review board (IRB) of the National
21 Center for AIDS/STD Control and Prevention of the China Center for Disease Control

1 Prevention (NCAIDS, China CDC). All participants provided written informed
2 consent before participation. Signed informed consent was obtained from each of the
3 participants prior to the interviews and blood collection.

4 **Methods**

5 **Study Design and Data Collection**

6 This study was designed under the WHO Surveillance of HIV drug resistance in
7 adults receiving ART for 48 months.^{10, 17, 18} Five provinces in China with highest
8 rate of transmission were selected to conduct a prospective cohort study with
9 a follow-up study at 12 months: Guangxi, Henan, Hubei, Xinjiang and Yunnan.
10 Participants were sampled from the 2008 National HIV Surveillance Database
11 through sequential sampling from each province. Participant eligibility criteria
12 included being age ≥ 18 years; having initiated NAFTP-sponsored first-line ART in
13 2008; having been ART-free before 2008; having been on ART for 36 ± 6 months in
14 2011; and providing consent to participate in the study.
15 Questionnaires administered by trained study personnel from provincial CDC in
16 private rooms using structured interviews collected data in 2011 and 2012. Each study
17 participant was assigned a confidential identification number used to label
18 questionnaire and blood specimen. Additional HIV-specific data including route of
19 transmission, initial ART regimen, latest ART regimen, ART distribution location and
20 CD4 cell count were collected from the 2011-2012 National HIV Surveillance

1 Database. There was no missing demographic data, missed questionnaire data was
2 feedbacked to local CDC for recollection at the time.

3 **Laboratory analysis**

4 Blood specimens were collected from all participants to determine CD4 cell count,
5 HIV-1 RNA viral load (VL), and HIV-1 drug resistance mutations in both 2011 and
6 2012. CD4 cell count estimation was conducted at provincial CDC laboratories using
7 flow cytometry (FACSC Calibur, BD Company, USA) within 24 hours after
8 specimen collection. Plasma was isolated and stored at -80°C at a provincial CDC
9 laboratory and then transferred to NCAIDS for testing HIV VL and drug mutation.
10 Plasma HIV RNA was quantified with real-time NASBA (NucliSense Easy Q,
11 bioMerieux, France) or COBAS (Roche Applied Biosystems, Germany) according to
12 manufacturer recommendations using in-house PCR (polymerase chain reaction),
13 both of the assays were performed automatically.¹⁹ Virologic failure was defined as
14 VL \geq 1000 copies/ml. According WHO protocol,²⁰ HIVDR tests were performed on
15 samples with VL \geq 1000 copies/ml. HIV-1 *pol* gene (protease 1-99 amino acids and
16 part of reverse transcriptase 1-252 amino acids) were amplified, purified and analyzed
17 using the Stanford HIV Drug Resistance Database (<https://hivdb.stanford.edu/hivdb>).
18 Levels of HIVDR were classified according to the algorithm of Stanford HIVdb
19 program. The scores are the sum of each mutation penalty score for a drug. Scores
20 less than 10 indicate susceptible; scores between 10 and 14 indicate potential low-
21 level resistance; scores between 15 and 29 indicate low-level resistance; scores

1 between 30 and 59 indicate intermediate resistance. Scores of 60 or greater indicate
2 high-level resistance. Any low-, intermediate-, or high-level resistance identified was
3 defined as HIVDR.²¹⁻²⁵

4 **Data analysis**

5 Questionnaire data were double-entered using Epidata 3.1 (The Epidata Association
6 Odense, Denmark). Statistical Analysis System (SAS 9.4, SAS Institute Inc., Cary,
7 NC, USA) was then used for data cleaning and analyses.

8 48-month risk for the outcomes of interest was calculated as the proportion of unique
9 persons who had experienced incident VF or HIVDR by the end of follow-up in 2012.

10 Covariates of interest were described using counts and percentages overall and by the
11 outcome of interest, stratified by gender. Univariate logistic regression models were
12 constructed to explore associations between covariates of interest and VF or HIVDR.
13 Odds ratios (OR) and 95% confidence intervals (CIs) are reported. Variables that
14 were significant ($P < 0.05$) in the univariate models were then fit into multivariate
15 logistic regression models assessment for removal of collinear variables that had the
16 weakest association with the outcome. Adjusted ORs (aOR) and 95% CIs were
17 presented. $P < 0.05$ was defined as statistically significant, and all tests were two
18 sided. Descriptive analysis on HIVDR mutation results was conducted among 27
19 HIVDR participants, stratified by sex.

20 **Results**

1 1100 subjects were selected using consecutive ID numbers from 2008 National
2 Surveillance Database; of those, 490 were lost follow-up by December, 2012. Among
3 those lost to follow up, 139 died, 55 emigrated, 134 lost contact, 17 refused to
4 participate, 65 stopped ART before 30 months, 36 transferred, 8 were under custody,
5 6 failed to provide a blood sample, 3 switched from ART to Tangcao tablet (an
6 antiviral Chinese herbal therapy), 2 became pregnant and switched to other regimens
7 and 1 was paralyzed. After excluding 74 participants for failing the eligibility criteria,
8 536 participants were included in the final 24-month analysis (Figure 1). The 48-
9 month risk of VF was 11.8% and risk of drug resistance was 5%.

10 Demographic and ART Information (Tables 1-2)

11 Of the 536 eligible participants, 51.8% were male; 76.5% were Han nationality; 45.0%
12 had an education level of elementary school or less; 56.2% were farmers; and 10.6%
13 were unemployed with the rest having regular income.

14 All regimens in this cohort remained 3TC-based from 2008 to 2012. Initiated
15 Nucleoside Reverse Transcriptase Inhibitors (NRTI) regimens included Zidovudine
16 (AZT) (n=349, 65.1%) or Stavudine (D4T) (n=187, 34.9%). 66 (12.3%) participants
17 later changed to TDF based regimen. Initiated Non-Nucleoside Reverse Transcriptase
18 Inhibitors (NNRTI) regimens included Nevirapine (NVP) (n=421, 78.5%) or
19 Etravirine (EFV) (n=115, 21.5%). 55 (10.3%) participants later changed to LPV/r
20 based regimen. 169 (31.5%) participants switched the initial ART regimen during
21 2008-2012, but no statistical significant difference was found in VF ($p=0.74$) and

1 HIVDR ($p=0.29$) risk between participants who switched regimens and participants
2 who did not switch regimens.
3 We found that 38.4% participants were hesitant to accept ART in the future, 36.8%
4 participants reported doubts whether ART was health promoting and 42.5%
5 participants did not report that poor ART adherence necessarily contributed to
6 HIVDR. Additionally, 40.5% of participants were not always satisfied with support
7 from friends or relatives. 472 (88.1%) participants reported not missing a dose in the
8 month prior to the date of the survey.
9 Multivariate model results (Table 3)
10 As shown in Table 3, minority male participants were at higher risk for both VF
11 (aOR=2.9, 95% CI: 1.1 to 7.3, P-value=0.02) and HIVDR (aOR=12.2, 95% CI: 1.8 to
12 84.8, P-value=0.01) compared to Han nationality male participants, while female
13 minorities were only at a higher risk for HIVDR (aOR=4.8, 95% CI: 1.2 to 19.7, P-
14 value=0.03).
15 Female participants initiating D4T-based regimens were at a higher risk for both VF
16 (aOR=2.5, 95% CI: 1 to 6.1, P-value=0.04) and HIVDR (aOR=3.6, 95% CI: 1 to 12.6,
17 P-value=0.05) versus those initiating an AZT-based regimen; interestingly, different
18 from their female counterparts, male participants showed no such association
19 (OR=0.6, 95% CI: 0.3 to 1.4, P-value=0.24). Also, female participants had a higher
20 risk of VF given adverse side-effects (aOR=2.3, 95% CI: 1 to 5.6, P-value=0.06).
21 Male participants with missed doses in the month prior to the survey were at a higher

1 risk of both VF (aOR=2.8, 95% CI: 1.1 to 7, P-value=0.03) and HIVDR (aOR=9.7, 95%
2 CI: 2.1 to 44.1, P-value<0.01) versus those without missed doses in the preceding
3 month. Conversely, missed doses in prior month was not significantly associated with
4 VF or HIVDR for women.

5 HIV Drug Resistance and Subtype (Table 4)

6 HIVDR identified in our study was consistency with the NFATP recommended ART
7 regimen. All 27 participants detected with drug resistance had NNRTI mutations, 21
8 (77.8%) had NRTI mutations. The dominant subtype was CRF07_BC for both males
9 (61.5%) and females (50%). All participants found with HIVDR had developed
10 HIVDR towards NNRTI; 85.7% male participants and 69.2% female developed
11 HIVDR toward NRTI; no Protease Inhibitor mutation was detected. There were no
12 CRF08_BC subtypes detected in the study population.

13 Discussion

14 The 48-month risk of VF was 11.8% and HIVDR was 5.0%, which indicated
15 relatively good treatment outcomes given meta-analysis suggested a 37-48 months
16 HIVDR prevalence ranging from 3.04%-47.92% in China,⁹ similar to studies in China
17 which estimated a one-year HIVDR incidence of 3.5% in 2009 and 2.1% in 2012.²⁶
18 ²⁷ Our study substantiates the finding that VF and HIVDR largely decreased since the
19 wide-spread of 3TC-based regimens.²⁸ Studies have shown mixed findings of gender
20 differences on ART adherence and treatment outcomes.^{14, 16, 29, 30} In our study, we
21 found male participants had slightly higher risk of VF (12.2% versus 11.2%, P-

1 value=0.72) but lower risk of HIVDR (2.4% versus 5.4%, P-value=0.69) than women.
2
3
4
5
6 Drug adherence and adverse effects influenced our outcomes differently for men
7
8
9 compared to women. Women's risks of VF and HIVDR were not associated with
10
11
12 missing doses in the past month, also, few women missed doses relative to men,
13
14 similar to two other studies in China suggesting women have better adherence
15
16 behaviors.^{31, 32} Male participants were at higher risk of both VF and HIVDR if they
17
18 reported missed doses. More detailed studies need to be conducted on the frequency
19
20 and factors associated with missing treatment. However, female participants showed a
21
22 higher risk of VF if they had adverse effect while men did not. This calls for further
23
24 research of what types of adverse effects are occurring and how they affect ART
25
26 adherence and virological outcomes across gender.
27
28 We found in this study that women, not men, who initiated D4T-based regimens were
29
30 more susceptible to VF (women vs. men OR=2.3 95% CI: 1.0 to 5.7 P-value=0.06)
31
32 and HIVDR (women vs. men OR=3.0 95%, CI: 0.8 to 11.3, P-value=0.11), consistent
33
34 with previous findings that D4T was more likely to increase the risk of mitochondrial
35
36 toxicity in women.^{33, 34} Mitochondrial toxicity caused by D4T had been reported to
37
38 cause many adverse effects such as lactic acidosis, lipodystrophy, and peripheral
39
40 neuropathy.^{35, 36} Following the WHO recommendation,³⁷ the NFATP advocated
41
42 switching the first-line regimen from D4T to TDF in 2012. The percentage of people
43
44 living with HIV initiating D4T-based regimen changed from 34.3% in 2010 to 10% in
45
46 2012 and 0.9% in 2014;³⁸ however, there were still 29.9% participants in our study
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 1 who were on D4T-based regimens in 2012. It was noteworthy that we did not see a
5
6 2 statistical difference in VF (OR=1.4 95%, CI: 0.4 to 4.2, P-value=0.60) and HIVDR
7
8
9 3 (OR=1.0, 95% CI: 0.2 to 4.2, P-value=0.98) between women who initiated and
10
11 4 remained on D4T-based regimens and those who switched to AZT/TDF based
12
13
14 5 regimens. It is possible that women switched regimens because of VF; however,
15
16 6 further studies need to be done to explore when to switch ART regimen for women
17
18
19 7 receiving D4T-based regimens. It is important to mention that data on ART adherence
20
21
22 8 and adverse effects were collected in 2012, when there were only four female
23
24
25 9 participants still using D4T-based regimens who experienced VF. The sample size
26
27
28 10 was not sufficient to explore whether D4T-based regimens affect drug adherence and
29
30
31 11 adverse effects for women.
32
33 12 Though not associated with the VF and HIVDR outcomes, 38.4% of study
34
35
36 13 participants reported that they would not 'always' be willing to take ART in the future,
37
38
39 14 36.8% reported not believing that ART is 'always' health promoting, and 42.5%
40
41
42 15 reported not believing that poor compliance 'always' contributed to HIVDR. As
43
44
45 16 willingness and these knowledge factors may impact more long-term VF and HIVDR
46
47
48 17 outcomes, the motivations behind willingness and knowledge about VF and HIVDR
49
50
51 18 warrant exploration.
52
53
54 19 Caution is needed when interpreting the study results from multivariate model that
55
56
57 20 older age (>45) was protective for HIVDR in men. There were only 4 male IDU
58
59
60 21 participants with older age (>45) in this study, the number is not sufficient to test for

1
2
3
4 1 interaction. There is no association between HIVDR and age (OR=6.5, 95% CI: 1.1 to
5
6 2 38.1, P-value=0.49) in the sub-analysis we did among male IDU participants , after
7
8
9 3 controlling for variables showed significant in the univariate model. A previous study
10
11 4 in HIV positive IDU population in China suggested that there is no association
12
13 5 between VF and sex or age.³⁹ In this study, 61.5% of male participants with HIVDR
14
15 6 became HIV infected via IDU, yet there were only 22.7% male IDU participants.
16
17 7 In addition, we found that younger (<45 years) IDU population were more likely to
18
19 8 miss doses (18.6%) compared to heterosexual transmission population (8.8%) and
20
21 9 blood transfusion transmission population (12.1%). This finding was consistent with
22
23 10 studies that implied younger males were at a higher risk of drug abuse.^{40, 41} This result
24
25 11 indicated that younger IDU population could be a main source of VF and HIVDR;
26
27 12 therefore they could be future targeted population for behavioral intervention.
28
29 13 The increased risk of VF and HIVDR in non-Han minorities, regardless of gender,
30
31 14 may be due to logistical, cultural, or social barriers faced by ethnic minorities which
32
33 15 limit their adherence to ART. It has been reported that minorities tend to have lower
34
35 16 social economic status than Han majorities, followed by lower education level and
36
37 17 fewer access to health facilities.⁴² It may be difficult for health professionals to reach
38
39 18 for some minorities because of their more remote geographic locations. Additionally,
40
41 19 several studies have reported that the percentage of high-risk populations such as
42
43 20 female sex workers (FSWs) and IDUs were higher in minorities than in Han
44
45 21 nationality.⁴³⁻⁴⁵ The causes of this increased VF and HIVDR risk warrants further
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 exploration, and ethnic minorities may be an important group to tailor adherence-
2 focused interventions in China. The finding that higher CD4 cell count at follow-up
3 was protective for VF and HIVDR was expected. NFATP changed treatment criteria
4 from CD4 cell count ≤ 200 cells/mm³ to CD4 cell count ≤ 350 cells/mm³ following the
5 WHO recommendation in 2011,^{7, 17, 46}. Our study indicated that male participants
6 who initiated treatment in 2008 at CD4 cell count ≥ 350 cells/mm³ were still at
7 higher risk towards VF (aOR=7.1, 95% CI: 1.1 to 45.8, P-value=0.04), supporting
8 possible clinical benefits of initiating ART at higher CD4 cell counts, < 500 cells/mm³
9 as per WHO recommendation in 2013.⁴⁷

10 Among participants infected by blood transmission, we only found HIVDR subtype B;
11 only one subtype C was found in participants infected with IDU, the dominant
12 subtype was CRF07_BC, found both in participants infected by heterosexual
13 transmission and IDU. The most common NNRTI mutation sites were K103N
14 (40.7%), K101E (22.2%) and V108I (22.2%); the most common NRTI mutation sites
15 were M184V (81.0 %) and K70R (19%). Interestingly, compared to a one-year
16 follow-up study in China with all participants initiated ART in 2011,⁴⁸ there is no
17 V108I in their study and we did not find K65R in our study.

18 Study findings should be interpreted in light of several limitations. Though we did not
19 account for transmitted drug resistance in this study, previous studies have found low
20 transmitted drug resistance risk ($< 5\%$) during this period⁴⁹⁻⁵¹ in China and we could
21 be fairly certain that participants were outcome free in 2008 as they were new ART

1 initiators. Another limitation of our study is that the outcomes were measured in 2011
2 and 2012, and thus we may be missing transient VF outcomes. Also, route of
3 transmission was collected in 2008 when assessing HIV infection among men who
4 have sex with men was not part of data collection instruments; additionally we do not
5 have data on sex worker status. Roughly half of the study participants selected for
6 possible inclusion in the study for having initiated first-line ART in 2008 were lost to
7 follow-up by 2012, creating a possible selection bias for individuals with better ART
8 adherence – this bias may underestimate the true VF and HIVDR risk and also limit
9 the generalizability of our findings to better adherers. Additionally, given the
10 demographic profile of the cohort, our findings are most generalizable to heterosexual
11 Han national who are married/cohabiting and working as agricultural labors in rural
12 areas. Misclassification of self-reported data is possible, though we do not expect this
13 misclassification to be differential by the outcome of interest and thus any such
14 information bias would bias our results toward the null.

15 **Conclusions**

16 We found female participants initiating D4T versus AZT-based regimens were more
17 vulnerable to VF and HIVDR, and we suggest future studies on whether and when to
18 change ART regimen for women initiated with D4T-based regimen. Poor adherence
19 was a risk factor among male participants who may benefit from reinforced adherence
20 counseling or social support. Increased VF and HIVDR risk among non-Han
21 minorities warrants further exploration, and ethnic minorities may be an important

1 group to tailor adherence-focused interventions in China. Also, this study indicated
2 that younger men who become infected through IDU may be groups to strategically
3 focus counseling and increased adherence support programs.

4 **Funding**

5 This study was supported by Guangxi Center for Disease Control and Prevention,
6 Nanning, China. The antiretroviral drugs used in this study were provided by NFATP.

7 **Contributions**

8 YR, WK, HX and YS designed the study. YR, HX, SL, LL, YM, HT, TZ, GS, HC,
9 WK, XL and PL collected the data. HC, TT and LL conducted laboratory analysis.
10 XL, WK analyzed the data. KW, VM, YR, WK, HX, LL and YS interpreted the data.
11 KW, VM, YR, WK, TT, and YS drafted the report. All authors reviewed, revised, and
12 approved the final report.

13 **Conflicts of Interest**

14 All authors declare that they have no conflicts of interest.

15 **Transparency Declarations**

16 Vincent C. Marconi has received fees from ViiV Healthcare.

17 **Conflicts of Data Sharing Statement**

18 No additional data available.

19

Table 1. Factors associated with virological failure (viral load ≥ 1000 copies/ml) stratified by sex

DEMOGRAPHIC FACTORS								
	Female				Male			
	Total	Virological failure Risk, N (%)	OR (95%CI)	P-value	Total	Virological failure Risk, N (%)	OR (95%CI)	P-value
Total	258	29 (11.2)			278	34 (12.2)		
Ethnicity								
Han nationality	191	19 (9.9)	1		219	20 (9.1)	1	
Other minorities	67	10 (14.9)	1.6 (0.7,3.6)	0.27	59	14 (23.7)	3.1 (1.5,6.6)	<0.01
Education								
Elementary school or less	134	15 (11.2)	1		107	12 (11.2)	1	
Junior school or more	124	14 (11.3)	1 (0.5,2.2)	0.98	171	22 (12.9)	1.2 (0.6,2.5)	0.68
Marital Status								
Single	59	6 (10.2)	1		75	9 (12)	1	
Married or Cohabited	199	23 (11.6)	1.2 (0.4,3.0)	0.77	203	25 (12.3)	1 (0.5,2.3)	0.94
Residence								
Rural	197	19 (9.6)	1		172	17 (9.9)	1	
City	61	10 (16.4)	1.8 (0.8,4.2)	0.15	106	17 (16)	1.7 (0.8,3.6)	0.13
Occupation								
Peasant	163	15 (9.2)	1		138	9 (6.5)	1	
Employee	64	11 (17.2)	2 (0.9,4.7)	0.09	114	17 (14.9)	2.5 (1.1,5.9)	0.03
Unemployed	31	3 (9.7)	1.1 (0.3,3.9)	0.93	26	8 (30.8)	6.4 (2.2,18.6)	<0.01
Age								

<35	73	6 (8.2)	1		53	7 (13.2)	1	
35-45	108	15 (13.9)	1.8 (0.7,4.9)	0.25	119	15 (12.6)	0.9 (0.4,2.5)	0.91
>45	77	8 (10.4)	1.3 (0.4,3.9)	0.65	106	12 (11.3)	0.8 (0.3,2.3)	0.73
Weight (kg)								
<50	89	14 (15.7)	1		49	7 (14.3)	1	
50-70	156	13 (8.3)	0.5 (0.2,1.1)	0.08	193	21 (10.9)	0.7 (0.3,1.8)	0.51
>70	13	2 (15.4)	1 (0.2,4.9)	0.97	36	6 (16.7)	1.2 (0.4,3.9)	0.76
HIV CHARACTERISTICS AND TREATMENT FACTORS								
Route of Infection								
Heterosexual Transmission	159	12 (7.5)	1		154	11 (7.1)	1	
Blood Transmission	86	13 (15.1)	2.2 (0.9,5)	0.07	61	10 (16.4)	2.5 (1,6.4)	0.04
Intravenous Drug use	13	4 (30.8)	5.4 (1.5,20.3)	0.01	63	13 (20.6)	3.4 (1.4,8)	0.01
Initial NRTI ART regimen								
AZT based regimen	161	11 (6.8)	1		188	26 (13.8)	1	
D4T based regimen	97	18 (18.6)	3.1 (1.4,6.9)	<0.01	90	8 (8.9)	0.6 (0.3,1.4)	0.24
Latest NRTI ART regimen								
AZT based regimen	181	15 (8.3)	1		195	27 (13.8)	1	
D4T based regimen	77	14 (18.2)	2.5 (1.1,5.4)	0.02	83	7 (8.4)	0.6 (0.2,1.4)	0.21
Switch ART regimen								
No	193	21 (10.9)	1		174	21 (12.1)	1	

Yes	65	8 (12.3)	1.2 (0.5,2.7)	0.75	104	13 (12.5)	1 (0.5,2.2)	0.92
ART drug distribution location								
County hospital or CDC	96	15 (15.6)	1		63	14 (22.2)	1	
Township hospital /village clinic /medication monitor	162	14 (8.6)	0.5 (0.2,1.1)	0.09	215	20 (9.3)	0.4 (0.2,0.8)	0.01
Adverse effects								
No	195	17 (8.7)	1		206	23 (11.2)	1	
Yes	63	12 (19)	2.5 (1.1,5.5)	0.03	72	11 (15.3)	1.4 (0.7,3.1)	0.36
CD4 cell/ml at baseline (2008)								
<350	244	28 (11.5)	1		272	31 (11.4)	1	
≥350	14	1 (7.1)	0.6 (0.1,4.7)	0.62	6	3 (50)	7.8 (1.5,40.2)	0.01
CD4 cell/ml at 36 months (2011)								
0-350	91	18 (19.8)	1		138	21 (15.2)	1	
≥350	167	11 (6.6)	0.3 (0.1,0.6)	<0.01	140	13 (9.3)	0.6 (0.3,1.2)	0.13
CD4 cell/ml at 48 months (2012)								
0-350	81	14 (17.3)	1		122	20 (16.4)	1	
≥350	177	15 (8.5)	0.4 (0.2,1)	0.04	156	14 (9)	0.5 (0.2,1)	0.06
DRUG COMPLIANCE FACTORS								
Missed doses								

in past month								
No	226	26 (11.5)	1		246	24 (9.8)	1	
Yes	32	3 (9.4)	0.8 (0.2,2.8)	0.72	32	10 (31.3)	4.2 (1.8,9.9)	<0.01
Willing to receive ART in the future								
Always	153	15 (9.8)	1		177	19 (10.7)	1	
Not always	105	14 (13.3)	1.4 (0.7,3.1)	0.38	101	15 (14.9)	1.5 (0.7,3)	0.32
Believe ART is health promoting								
Always	158	16 (10.1)	1		181	19 (10.5)	1	
Not always	100	13 (13)	1.3 (0.6,2.9)	0.48	97	15 (15.5)	1.6 (0.8,3.2)	0.24
Believe poor compliance contribute to HIVDR								
Always	139	16 (11.5)	1		169	19 (11.2)	1	
Not always	119	13 (10.9)	0.9 (0.4,2.1)	0.88	109	15 (13.8)	1.3 (0.6,2.6)	0.53
Degree of satisfaction on support of friends or relatives								
Always satisfied	153	15 (9.8)	1		166	17 (10.2)	1	
Not always satisfied	105	14 (13.3)	1.4 (0.7,3.1)	0.38	112	17 (15.2)	1.6 (0.8,3.2)	0.22
Frequency of taking drugs reminded by friends or								

relatives								
Often	172	19 (11)	1		168	22 (13.1)	1	
Not often	86	10 (11.6)	1.4 (0.7,3.1)	0.38	110	12 (10.9)	0.8 (0.4,1.7)	0.58
Frequency of taking drugs reminded by doctors								
Often	178	23 (12.9)	1		184	28 (15.2)	1	
Not often	80	6 (7.5)	0.5 (0.2,1.4)	0.19	94	6 (6.4)	0.4 (0.2,1)	0.03

*OR: odds ratio; CI: confidence interval; HIVDR: HIV drug resistance; ART: antiretroviral treatment; AZT: Zidovudine; D4T: Stavudine

Table 2. Factors associated with HIVDR (viral load ≥ 1000 copies/ml with drug resistance) stratified by sex

DEMOGRAPHIC FACTORS								
	Female				Male			
	Total	HIVDR Risk N (%)	OR (95%CI)	P-value	Total	HIVDR Risk N (%)	OR (95%CI)	P-value
	258	14 (5.4)			278	13 (4.7)		
Ethnicity								
Han nationality	191	6 (3.1)	1		219	5 (2.3)	1	
Other minorities	67	8 (11.9)	4.2 (1.4 to 12.5)	0.01	59	8 (13.6)	6.7 (2.1 to 21.4)	<0.01
Education								
Elementary school or less	134	5 (3.7)	1		107	5 (4.7)	1	
Junior school or more	124	9 (7.3)	2 (0.7 to 6.2)	0.22	171	8 (4.7)	1 (0.3 to 3.1)	1
Marital Status								
Single	59	4 (6.8)	1		75	4 (5.3)	1	
Married or Cohabited	199	10 (5)	0.7 (0.2 to 2.4)	0.60	203	9 (4.4)	0.8 (0.2 to 2.8)	0.75
Residence								
Rural	197	7 (3.6)	1		172	5 (2.9)	1	
City	61	7 (11.5)	3.5 (1.2 to 10.5)	0.02	106	8 (7.5)	2.7 (0.9 to 8.6)	0.09
Occupation								
Peasant	163	5 (3.1)	1		138	0	1	
Employee	64	6 (9.4)	3.3 (1 to 11.1)	0.06	114	9 (7.9)	2 (1 to 12.6)	<0.01
Unemployed	31	3 (9.7)	3.4 (0.8 to 15)	0.11	26	4 (15.4)	3 (1 to 13.4)	<0.01

Age								
<35	73	5 (6.8)	1		53	6 (11.3)	1	
35-45	108	6 (5.6)	0.8 (0.2 to 2.7)	0.72	119	6 (5)	0.4 (0.1 to 1.4)	0.15
>45	77	3 (3.9)	0.6 (0.1 to 2c.4)	0.43	106	1 (0.9)	0.1 (0 to 0.6)	0.02
Weight (kg)								
<50	89	8 (9)	1		49	4 (8.2)	1	
50-70	156	4 (2.6)	0.3 (0.1 to 0.9)	0.04	193	7 (3.6)	0.4 (0.1 to 1.5)	0.19
>70	13	2 (15.4)	1.8 (0.3 to 9.8)	0.47	36	2 (5.6)	0.7 (0.1 to 3.8)	0.64
HIV CHARACTERISTICS AND TREATMENT FACTORS								
Route of Infection								
Heterosexual Transmission	159	8 (5)	1		154	2 (0.6)	1	
Blood Transmission	86	4 (4.7)	0.9 (0.3 to 3.2)	0.9	61	3 (2)	3.9 (0.6 to 24.1)	0.14
Intravenous Drug use	13	2 (15.4)	3.4 (0.6 to 18.2)	0.15	63	8 (10.5)	11.1 (2.3 to 53.7)	<0.01
Initial NRTI ART regimen								
AZT based regimen	161	5 (3.1)	1		188	10 (2.9)	1	
D4T based regimen	97	9 (9.3)	3.2 (1 to 9.8)	0.04	90	3 (1.6)	0.6 (0.2 to 2.3)	0.47
Latest ART regimen								
AZT based regimen	181	8 (4.4)	1		195	12 (3.2)	1	
D4T based regimen	77	6 (7.8)	1.8 (0.6 to 5.5)	0.28	83	1 (0.6)	0.2 (0 to 1.5)	0.11
Switch ART regimen								

No	193	10 (5.2)	1		174	6 (3.4)	1	
Yes	65	4 (6.2)	1.2 (0.4 to 4)	0.76	104	7 (6.7)	2 (0.7 to 6.2)	0.22
Adverse effect								
No	195	9 (4.6)	1		206	10 (4.9)	1	
Yes	63	5 (7.9)	1.8 (0.6 to 5.5)	0.32	72	3 (4.2)	0.9 (0.2 to 3.2)	0.81
CD4 cell at baseline (2008)								
<350	244	14 (5.7)			272	12 (2.3)	1	
≥350	14	0	-	0.36	6	1 (5)	4.3 (0.5 to 40)	0.2
CD4 cell at 36 months (2011)								
0-350	91	9 (9.9)	1		138	11 (4.8)	1	
≥350	167	5 (3)	0.3 (0.1 to 0.9)	0.03	140	2 (0.7)	0.2 (0 to 0.8)	0.02
CD4 cell at 48 months (2012)								
0-350	81	7 (8.6)	1		122	11 (5.4)	1	
≥350	177	7 (4)	0.4 (0.1 to 1.3)	0.13	156	2 (0.6)	0.1 (0 to 0.6)	0.01
DRUG COMPLIANCE FACTORS								
Missed doses in past month								
No	226	13 (5.8)	1		246	6 (2.4)	1	
Yes	32	1 (3.1)	0.5 (0.1 to 4.2)	0.55	32	7 (21.9)	11.2 (3.5 to 35.9)	<0.01

* ART drug distribution location, Willing to receive ART in the future, Believe ART is health promoting, Believe poor compliance contribute to HIVDR, Degree of satisfaction on support of friends or relatives, Frequency of taking drugs reminded by friends or relatives, Frequency of taking drugs reminded by doctors are not displayed for no statistical significant difference between categorizes.

* OR: odds ratio; CI: confidence interval; HIVDR: HIV drug resistance; ART: antiretroviral treatment; AZT: Zidovudine; D4T: Stavudine

Table 3. Multivariate Models of Factors associated with virological failure (viral load ≥ 1000 copies/ml) and HIVDR (viral load ≥ 1000 copies/ml with drug resistance) stratified by sex

Variables	FEMALE				MALE			
	Virological Failure		HIVDR		Virological Failure		HIVDR	
	Adjusted OR (95%CI)	P-value	Adjusted OR (95%CI)	P-value	Adjusted OR (95%CI)	P-value	Adjusted OR (95%CI)	P-value
Total								
Ethnicity								
Han nationality			1		1		1	
Other minorities			4.8 (1.2 to 19.7)	0.03	2.9 (1.1 to 7.3)	0.02	12.2 (1.8 to 84.8)	0.01
Residence								
Rural			1					
City			2.4 (0.6 to 9.5)	0.22				
Age								
<35							1	
35-45							0.3 (0.1 to 1.4)	0.12
>45							0.03 (0 to 0.6)	0.02
Weight (kg)								
<50			1					
50-70			0.3 (0.1 to 1.1)	0.08				
>70			4.2 (0.6 to 30)	0.15				
Route of Infection								
Heterosexual Transmission	1				1		1	
Blood Transmission	1.2 (0.5 to 3)	0.74			1.8 (0.6 to 5.8)	0.33	7 (0.8 to 64.4)	0.09

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Intravenous Drug use	4.1 (1 to 17.7)	0.06			2.1 (0.8 to 5.4)	0.12	2.3 (0.3 to 16.1)	0.41
Initial NRTI ART regimen								
AZT based regimen	1		1					
D4T based regimen	2.5 (1 to 6.1)	0.04	3.6 (1 to 12.6)	0.05				
ART drug distribution location								
County hospital or CDC					1			
Township hospital /village clinic /medication monitor					0.5 (0.2 to 1.3)	0.18		
Adverse effect								
No	1							
Yes	2.3 (1 to 5.6)	0.06						
CD4 cell at baseline (2008)								
<350					1			
≥350					7.1 (1.1 to 45.8)	0.04		
CD4 cell at 36 months (2011)								
<350	1		1				1	
≥350	0.4 (0.2 to 1.1)	0.07	0.3 (0.1 to 0.9)	0.04			0.3 (0 to 1.9)	0.2
CD4 cell at 48								

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

months (2012)					
<350	1			1	
≥350	0.6 (0.3 to 1.6)	0.36		0.1 (0 to 1)	0.05
Missed doses in past month					
No			1	1	
Yes			2.8 (1.1 to 7)	0.03	9.7 (2.1 to 44.1) <0.01
Frequency of taking drugs reminded by doctors					
Often			1		
Not often			0.4 (0.2 to 1.2)	0.12	

* OR: odds ratio; CI: confidence interval; HIVDR: HIV drug resistance; ART: antiretroviral treatment; AZT: Zidovudine; D4T: Stavudine

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 4. HIV Drug Resistance and Subtype among 27 patients with HIVDR Mutation Detected at 2011 and/or 2012 stratified by sex

	FEMALE (%)	MALE (%)	MUTATIONS	N (%)
Overall	14	13		
Subtype				
B	5 (35.7)	3 (23.1)		
C		1 (7.7)		
CRF01_AE	2 (14.3)	1 (7.7)		
CRF07_BC	7 (50)	8 (61.5)		
Antiretroviral Drug				
Non-nucleoside reverse transcriptase inhibitors (NNRTI,any)	14 (100)	13 (100)	NNRTI Mutations(total)	27
Efavirenz (EFV)	14 (100)	13 (100)	V90I	1 (3.7)
Nevirapine (NVP)	14 (100)	13 (100)	A98G	2 (7.4)
Etravirine (ETR)	6 (42.9)	8 (61.5)	K101E	6 (22.2)
			K103N	11 (40.7)
			V106A	4 (14.8)
			V108I	6 (22.2)
			E138A	1 (3.7)
			V179D/F	3 (11.1)
			Y181C	5 (18.5)
			G190A	5 (18.5)
			H221Y	1 (3.7)
			P225H	3 (11.1)
			F227L	1 (3.7)
			M230L	1 (3.7)

Nucleoside reverse transcriptase inhibitors (NRTI,any)	12 (85.7)	9 (69.2)	NRTI Mutations(total)	21
Lamivudine (3TC)	12 (85.7)	9 (69.2)	A62V	1 (4.8)
Azidothymidine (AZT)	2 (14.3)	2 (15.4)	D67G	1 (4.8)
Tenofovir (TDF)	1 (7.1)	3 (23.1)	T69N	2 (9.5)
Stavudine (D4T)	3 (21.4)	3 (23.1)	K70R/Q	4 (19)
Didanosine (DDI)	5 (35.7)	3 (23.1)	V75I/M	2 (9.5)
Abcavir (ABC)	12 (85.7)	9 (69.2)	M184V	17 (81.0)
Emtricitabine (FTC)	12 (85.7)	9 (69.2)	T215N	1 (4.8)
			K219E/Q	2 (9.5)
Protease inhibitors (PI,any)	0	0	PI Mutations(total)	0

*NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitors; NRTI: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors; PI: Protease Inhibitor

References

1. Hong SY, Nachega JB, Kelley K et al. The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention. *Infectious disorders drug targets* 2011; **11**: 124-33.
2. Gabillard D, Lewden C, Ndoye I et al. Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration. *Journal of acquired immune deficiency syndromes* 2013; **62**: 555-61.
3. Montaner JS, Lima VD, Harrigan PR et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. *PloS one* 2014; **9**: e87872.
4. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. *The New England journal of medicine* 1999; **341**: 1865-73.
5. Wang X, Yang L, Li H et al. Factors associated with HIV virologic failure among patients on HAART for one year at three sentinel surveillance sites in China. *Current HIV research* 2011; **9**: 103-11.
6. Zhang F, Dou Z, Ma Y et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. *Annals of internal medicine* 2009; **151**: 241-51, W-52.
7. Chinese Center of Disease and Control. Manual of the National Free Antiretroviral Treatment, 2007 edition 2007.
8. People's Republic of China (2008) UNGASS Country Progress Report. *Beijing: People's Republic of China* 2007.
9. Liu H, Ma Y, Su Y et al. Emerging trends of HIV drug resistance in Chinese HIV-infected patients receiving first-line highly active antiretroviral therapy: a systematic review and meta-analysis. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2014; **59**: 1495-502.
10. Djarma O, Nguyen Y, Renois F et al. Continuous free access to HAART could be one of the potential factors impacting on loss to follow-up in HAART-eligible patients living in a resource-limited setting: N'djamena, Chad. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2014; **108**: 735-8.
11. DeGruttola V, Dix L, D'Aquila R et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. *Antiviral therapy* 2000; **5**: 41-8.

12. Liao L, Xing H, Su B et al. Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China. *Aids* 2013; **27**: 1815-24.
13. Hare AQ, Ordonez CE, Johnson BA et al. Gender-specific risk factors for virologic failure in KwaZulu-Natal: automobile ownership and financial insecurity. *AIDS and behavior* 2014; **18**: 2219-29.
14. Berg KM, Demas PA, Howard AA et al. Gender differences in factors associated with adherence to antiretroviral therapy. *Journal of general internal medicine* 2004; **19**: 1111-7.
15. Floridia M, Giuliano M, Palmisano L et al. Gender differences in the treatment of HIV infection. *Pharmacological research* 2008; **58**: 173-82.
16. Moore AL, Mocroft A, Madge S et al. Gender differences in virologic response to treatment in an HIV-positive population: a cohort study. *Journal of acquired immune deficiency syndromes* 2001; **26**: 159-63.
17. World Health Organization. Surveillance Of HIV Drug Resistance In Adults Receiving Art (Acquired Hiv Drug Resistance). Accessed July 2014. 2014.
18. Bennett DE, Myatt M, Bertagnolio S et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. *Antiviral therapy* 2008; **13 Suppl 2**: 25-36.
19. Gaydos CA, Rizzo-Price PA, Balakrishnan P et al. Impact of international laboratory partnerships on the performance of HIV/sexually transmitted infection testing in five resource-constrained countries. *International journal of STD & AIDS* 2011; **22**: 645-52.
20. Organization WH. World Health Organization Protocol for Population Based Monitoring of HIV Drug Resistance Emerging During Treatment and Related Program Factors at Sentinel Antiretroviral Therapy Clinics.
21. Jiang Y, Qiu M, Zhang G et al. Quality assurance in the HIV/AIDS laboratory network of China. *International journal of epidemiology* 2010; **39 Suppl 2**: ii72-8.
22. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2006; **42**: 1608-18.
23. Yan H, Yu H, Xing W et al. Development of a proficiency testing program for the HIV-1 BED incidence assay in China. *Scientific reports* 2014; **4**: 4512.
24. Zhong P, Pan Q, Ning Z et al. Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. *AIDS research and human retroviruses* 2007; **23**: 847-56.
25. !!! INVALID CITATION !!! .
26. Xing H, Wang X, Liao L et al. Incidence and associated factors of HIV drug resistance in Chinese HIV-infected patients receiving antiretroviral treatment. *PloS one* 2013; **8**: e62408.

- 1
2
3 27. Wang J, He C, Hsi JH et al. Virological outcomes and drug resistance in
4 Chinese patients after 12 months of 3TC-based first-line antiretroviral treatment,
5 2011-2012. *PLoS One* 2014; **9**: e88305.
6
7 28. Xing H, Ruan Y, Hsi JH et al. Reductions in virological failure and drug
8 resistance in Chinese antiretroviral-treated patients due to lamivudine-based regimens,
9 2003–12. *Journal of Antimicrobial Chemotherapy* 2015: dkv078.
10
11 29. Nicastrì E, Leone S, Angeletti C et al. Sex issues in HIV-1-infected persons
12 during highly active antiretroviral therapy: a systematic review. *The Journal of*
13 *antimicrobial chemotherapy* 2007; **60**: 724-32.
14
15 30. Puskas CM, Forrest JI, Parashar S et al. Women and vulnerability to HAART
16 non-adherence: a literature review of treatment adherence by gender from 2000 to
17 2011. *Current HIV/AIDS reports* 2011; **8**: 277-87.
18
19 31. Dou Z, Xu J, Jiao JH et al. Gender difference in 2-year mortality and
20 immunological response to ART in an HIV-infected Chinese population, 2006-2008.
21 *PloS one* 2011; **6**: e22707.
22
23 32. Sabin LL, Desilva MB, Hamer DH et al. Barriers to adherence to antiretroviral
24 medications among patients living with HIV in southern China: a qualitative study.
25 *AIDS care* 2008; **20**: 1242-50.
26
27 33. Wester CW, Okezie OA, Thomas AM et al. Higher-than-expected rates of
28 lactic acidosis among highly active antiretroviral therapy-treated women in Botswana:
29 preliminary results from a large randomized clinical trial. *Journal of acquired immune*
30 *deficiency syndromes* 2007; **46**: 318-22.
31
32 34. Goedecke JH, Micklesfield LK, Levitt NS et al. Effect of different
33 antiretroviral drug regimens on body fat distribution of HIV-infected South African
34 women. *AIDS research and human retroviruses* 2013; **29**: 557-63.
35
36 35. Feleke Y, Fekade D, Mezegebu Y. Prevalence of highly active antiretroviral
37 therapy associated metabolic abnormalities and lipodystrophy in HIV infected
38 patients. *Ethiopian medical journal* 2012; **50**: 221-30.
39
40 36. Moyle GJ, Nelson MR, Hawkins D et al. The use and toxicity of didanosine
41 (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT). *The*
42 *Quarterly journal of medicine* 1993; **86**: 155-63.
43
44 37. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and
45 Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva,
46 2013.
47
48 38. Dou Z, Zhang F, Zhao Y et al. Progress on China's national free antiretroviral
49 therapy strategy in 2002-2014. *Chinese Journal Epidemiology* 2015; **36**: 1345-50.
50
51 39. Leng X, Liang S, Ma Y et al. HIV virological failure and drug resistance
52 among injecting drug users receiving first-line ART in China. *BMJ open* 2014; **4**:
53 e005886.
54
55 40. Wu Z, Zhang J, Detels R et al. Characteristics of risk-taking behaviors, HIV
56 and AIDS knowledge, and risk perception among young males in southwest China.
57
58
59
60

1
2
3 *AIDS education and prevention* : official publication of the International Society for
4 *AIDS Education* 1997; **9**: 147-60.

5
6 41. Yang H, Li X, Stanton B et al. Heterosexual transmission of HIV in China: a
7 systematic review of behavioral studies in the past two decades. *Sexually transmitted*
8 *diseases* 2005; **32**: 270-80.

9
10 42. Myers Jr SL, Xiaoyan G, Cruz BC. Ethnic minorities, race, and inequality in
11 China: A new perspective on racial dynamics. *Review of Black Political Economy*
12 2013; **40**: 231.

13
14 43. Zoufaly A, Jochum J, Hammerl R et al. Virological failure after 1 year of first-
15 line ART is not associated with HIV minority drug resistance in rural Cameroon. *The*
16 *Journal of antimicrobial chemotherapy* 2015; **70**: 922-5.

17
18 44. Shou L, WANG QX, Lei N et al. The changing trends of HIV/AIDS in an
19 ethnic minority region of China: modeling the epidemic in Liangshan prefecture,
20 Sichuan Province. *Biomedical and Environmental Sciences* 2013; **26**: 562-70.

21
22 45. Zhang L, Zhu J, Rui B et al. High HIV risk among Uigur minority ethnic drug
23 users in northwestern China. *Tropical Medicine & International Health* 2008; **13**:
24 814-7.

25
26 46. Chinese Center for Disease Control and Prevention. Manual of the National
27 Free Antiretroviral Treatment, third edition. Accessed 2013 Jun 12. . 2013.

28
29 47. World Health Organization. *Consolidated guidelines on general HIV care and*
30 *the use of antiretroviral drugs for treating and preventing HIV infection:*
31 *recommendations for a public health approach*: World Health Organization, 2013.

32
33 48. Xing H, Ruan Y, Hsi JH et al. Reductions in virological failure and drug
34 resistance in Chinese antiretroviral-treated patients due to lamivudine-based regimens,
35 2003-12. *The Journal of antimicrobial chemotherapy* 2015; **70**: 2097-103.


36
37 49. Liao L, Xing H, Shang H et al. The prevalence of transmitted antiretroviral
38 drug resistance in treatment-naive HIV-infected individuals in China. *Journal of*
39 *acquired immune deficiency syndromes* 2010; **53 Suppl 1**: S10-4.

40
41 50. Zhao K, Kang W, Liu Q et al. Genotypes and transmitted drug resistance
42 among treatment-naive HIV-1-infected patients in a northwestern province, China:
43 trends from 2003 to 2013. *PloS one* 2014; **9**: e109821.

44
45 51. Su Y, Zhang F, Liu H et al. The prevalence of HIV-1 drug resistance among
46 antiretroviral treatment naive individuals in mainland China: a meta-analysis. *PloS*
47 *one* 2014; **9**: e110652.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Figure of exclusion on study cohort



1. None HIV-related death.

215x279mm (300 x 300 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Page	Recommendation
Title and abstract	1	2	(a) Indicate the study's design with a commonly used term in the title or the abstract
		2-3	(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction			
Background/rationale	2	5	Explain the scientific background and rationale for the investigation being reported
Objectives	3	6	State specific objectives, including any prespecified hypotheses
Methods			
Study design	4	7	Present key elements of study design early in the paper
Setting	5	7	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	7	(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
			<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls
			<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants
			(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed
			<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	8-9	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	9	Describe any efforts to address potential sources of bias
Study size	10	9	Explain how the study size was arrived at
Quantitative variables	11	9	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	9	(a) Describe all statistical methods, including those used to control for confounding
			(b) Describe any methods used to examine subgroups and interactions
			(c) Explain how missing data were addressed
			(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy
			(e) Describe any sensitivity analyses

Results

Participants	13*	9	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		9-10	(b) Give reasons for non-participation at each stage
		19	(c) Consider use of a flow diagram
Descriptive data	14*	10	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
			(b) Indicate number of participants with missing data for each variable of interest
		10	(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	10	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time
			<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure
			<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	11,9	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		8	(b) Report category boundaries when continuous variables were categorized
			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	14-15	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18	12	Summarise key results with reference to study objectives
Limitations	19	16	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	12-16	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	17	Discuss the generalisability (external validity) of the study results

Other information

Funding	22	18	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
---------	----	----	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Predictors of HIV Virologic Failure And Drug Resistance In Chinese Patients After 48 Months Of Antiretroviral Treatment, 2008-2012 : A Prospective Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016012.R2
Article Type:	Research
Date Submitted by the Author:	24-Jul-2017
Complete List of Authors:	<p>Kan, Wei; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China; Emory University School of Public Health, Department of Epidemiology</p> <p>Teng, Tao; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China</p> <p>Liang, Shujia; Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention</p> <p>Ma, Yanling; Yunnan Center for Disease Control and Prevention, Kunming, China,</p> <p>Tang, Heng; Hubei Center for Disease Control and Prevention</p> <p>Zuohela, Tuerdi; Xinjiang Uighur Autonomous Region Center for Disease Control and Prevention</p> <p>Sun, Guoqing; Henan Province Center for Disease Control and Prevention</p> <p>He, Cui; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China,</p> <p>Wall, Kristin; Emory University School of Public Health, Department of Epidemiology</p> <p>Marconi, Vincent; Emory University School of Public Health, Department of Global Health; Emory University School of Medicine, Division of Infectious</p> <p>Liao, Lingjie; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China,</p> <p>Leng, Xuebing; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China,</p> <p>Liu, Pengtao ; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China</p> <p>Ruan, Yuhua; Chinese Center for AIDS/STD Control and Prevention, Division of Virology and Immunology</p> <p>Xing, Hui; State Key Laboratory for Infectious Disease Prevention and</p>

	Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China, Shao, Yiming; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	Public health
Keywords:	Antiretroviral Treatment, Virological Failure, Drug Resistance, Gender Difference, HIV & AIDS < INFECTIOUS DISEASES>

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Predictors of HIV Virologic Failure And Drug Resistance In Chinese Patients**
2 **After 48 Months Of Antiretroviral Treatment, 2008-2012 : A Prospective**
3 **Corhort Study**

5 Wei Kan^{1,7*}, Tao Teng^{1*}, Shujia Liang², Yanling Ma³, Heng Tang⁴, Tuerdi Zuohela⁵,
6 Guoqing Sun⁶, Cui He¹, Kristin M. Wall⁷, Vincent C. Marconi^{8,9}, Lingjie Liao¹,
7 Xuebing Leng¹, Pengtao Liu¹, Yuhua Ruan¹, Hui Xing¹, Yiming Shao¹

- 8
9 1. State Key Laboratory for Infectious Disease Prevention and Control, National
10 Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control
11 and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of
12 Infectious Diseases, Beijing, China
13 2. Guangxi Center for Disease Control and Prevention, Nanning, China
14 3. Yunnan Center for Disease Control and Prevention, Kunming, China
15 4. Hubei Center for Disease Control and Prevention, Wuhan, China
16 5. Xinjiang Autonomous Region Center for Disease Control and Prevention,
17 Urumqi, China
18 6. Henan Center for Disease Control and Prevention, Zhengzhou, China
19 7. Department of Epidemiology, Rollins School of Public Health, Emory University,
20 Atlanta, Georgia.
21 8. Department of Global Health, Rollins School of Public Health, Emory University,
22 Atlanta, Georgia.
23 9. Division of Infectious Diseases, Emory University School of Medicine, Atlanta,
24 Georgia

25
26 *These authors contributed equally to this work

27 Running head: Virologic failure and drug resistance among HIV+ Chinese ART
28 patients

1 **Body: 3,111**

2 **ABSTRACT**

3 **Objective:** To explore factors associated with HIV virologic failure (VF) and HIV
4 drug resistance (HIVDR) among HIV-positive Chinese individuals four years after
5 initiating first-line 3TC-based antiretroviral treatment (ART) in 2008 at five sentinel
6 sites.

7 **Design:** First-line ART initiators who were previously treatment naïve were selected
8 using consecutive ID numbers from the 2008 National Surveillance Database into a
9 prospective cohort study. Questionnaires and Blood samples were collected in 2011
10 and 2012 to assess the outcomes of interest: VF (defined as viral load \geq 1000
11 copies/ml) and HIVDR (defined as VF with genetic drug resistant mutations).
12 Questionnaires and data from National Surveillance Database assessed demographics
13 and drug adherence data.

14 **Results:** 536 individuals with HIV were analyzed; the 4-year risk of VF was
15 63(11.8%) and HIVDR was 27(5.0%). Female participants initiating D4T-based
16 regimens were more susceptible to both VF (adjusted odds ratio, aOR=2.5, 95% CI:
17 1-6.1, P-value=0.04) and HIVDR (aOR=3.6, 95% CI: 1 to 12.6, P-value=0.05) versus
18 AZT-based regimens. Male participants missing doses in past month were more
19 susceptible to both VF (aOR=2.8, 95% CI: 1.1 to 7, P-value=0.03) and HIVDR
20 (aOR=9.7, 95% CI: 2.1 to 44.1, P-value<0.01). Participants of non-Han nationality
21 were of increased risk for HIVDR (aOR from 4.8-12.2, P-value<0.05) and non-Han

1 men were at increased risk for VF (aOR=2.9, 95% CI: 1.1 to .3, P-value=0.02). All 27
2 participants detected with HIVDR had non-nucleoside reverse-transcriptase inhibitor
3 (NNRTI) mutations, 21 (77.8%) also had NRTI mutations, and no protease inhibitor
4 mutations were detected.

5 **Conclusions:** Our findings suggest successful treatment outcomes at 4-years for
6 roughly 90% of patients. We suggest conducting further study on whether and when
7 to change ART regimen for women initiated with D4T-based regimen, and
8 reinforcing adherence counseling for men. Increased VF and HIVDR risk among non-
9 Han minorities warrants further exploration, and ethnic minorities may be an
10 important group to tailor adherence-focused interventions.

11 **Strengths and limitations of this study**

- 12 ▪ We studied 48-month risk of VF and HIVDR and their associations with
13 demographic and behavioral information among individuals across five
14 sentinel sites.
- 15 ▪ Study found drug adherence and adverse effects influenced VF and HIVDR
16 differently across gender..
- 17 ▪ The outcomes were measured in 2011 and 2012, and thus we may be missing
18 transient VF outcomes.

1
2
3 1 **Key words:** HIV, Antiretroviral Treatment, Virological Failure, Drug Resistance,
4 2 Gender Differences, China
5
6
7 3

8 4 **Corresponding author:**
9

10 5 Yiming Shao

11 6 State Key Laboratory for Infectious Disease Prevention and Control, and National
12 7 Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control
13 8 and Prevention, Beijing, China
14

15 9 No. 155 Changbai Road, Changping District, Beijing 102206, P. R. China
16

17 10 Telephone: + 86-10-58900647 Fax: +86-10-58900980
18

19 11 E-mail: yshao08@gmail.com
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Introduction

2 Antiretroviral treatment (ART) has dramatically improved health outcomes and
3 decreased HIV-associated morbidity and mortality through virologic suppression and
4 subsequent CD4 recovery.¹⁻⁴ In 2003, China launched a National Free Antiretroviral
5 Treatment Program (NFATP) that includes life-long provision of free ART for people
6 living with HIV who met the national treatment criteria.^{5,6} The national treatment
7 criteria from 2008 to 2011 were: (1) CD4 cell count $\leq 200/\text{mm}^3$; (2) World Health
8 Organization (WHO) stage III/IV diseases; or (3) willingness to receive ART,
9 regardless of criteria 1 and 2.⁷

10 The State Council AIDS Working Committee Office and the United Nations Theme
11 Group on AIDS estimated that there were more than 700,000 persons living with HIV
12 in China in 2008, and more than 52,000 individuals with HIV across 31 provinces,
13 autonomous regions, and municipalities had received ART (made freely available by
14 the NFATP) by August 2008.⁸

15 With the rapid scale-up of treatment and challenges with adherence, virologic failure
16 (VF) and HIV drug resistance (HIVDR) are ever present and mounting concerns.
17 Incomplete virologic suppression, a major cause of HIVDR, not only compromises
18 therapeutic efficacy for the individual receiving treatment, increasing the risk of viral
19 rebound and opportunistic infections, but also increases the risk of transmitting drug
20 resistant strains to other individuals in the general population.^{9,10,11}

1
2
3
4 1 Observational studies in China have documented the prevalence of VF and HIVDR
5
6 2 strains among treated individuals living with HIV. A cross-sectional study conducted
7
8
9 3 in Yunnan, Guangxi and Xinjiang provinces in 2010 stated that one-year HIVDR
10
11 4 prevalence was 4.1%⁵. VF prevalence for sexual transmitted population and
12
13
14 5 intravenous drug users (IDUs) were 8.3% and 19.3%, separately. A 6-year follow-up
15
16
17 6 study in 2010 suggested an incidence of 14.1 per 100 person-year for VF and 11.9 per
18
19
20 7 100 person-year for HIVDR among former plasma donors in Anhui Province.¹²
21
22 8 NFATP recommended to switch the first-line regimen from Didanosine (DDI) to
23
24 9 Lamivudine (3TC) in 2008, and there are few nationwide, prospective studies in
25
26
27 10 China reporting frequency or predictors of VF and HIVDR for people after initiating
28
29
30 11 3TC based regimens.
31
32 12 The aim of this study is to evaluate predictors of VF and HIVDR in a prospective
33
34 13 cohort of Chinese HIV individuals with HIV four years after first initiating first-line
35
36
37 14 3TC-based ART in 2008 at five sentinel sites. We stratified our analyses by gender
38
39
40 15 based on conflicting findings on gender differences both in virological responses and
41
42
43 16 drug resistance to different ART regimen, as well as gender differences in ART
44
45
46 17 adherence.¹³⁻¹⁶ To our knowledge, this is the first long-term study to evaluate VF and
47
48
49 18 HIVDR on 3TC-based regimens.

19 **Ethics Statement**

20 The study was approved by the institutional review board (IRB) of the National
21 Center for AIDS/STD Control and Prevention of the China Center for Disease Control

1 Prevention (NCAIDS, China CDC). All participants provided written informed
2 consent before participation. Signed informed consent was obtained from each of the
3 participants prior to the interviews and blood collection.

4 **Methods**

5 **Study Design and Data Collection**

6 This study was designed under the WHO Surveillance of HIV drug resistance in
7 adults receiving ART for 48 months.^{10, 17, 18} Five provinces in China with highest
8 rate of transmission were selected to conduct a prospective cohort study with
9 a follow-up study at 12 months: Guangxi, Henan, Hubei, Xinjiang and Yunnan.

10 Participants were sampled from the 2008 National HIV Surveillance Database
11 through sequential sampling from each province. Participant eligibility criteria
12 included being age ≥ 18 years; having initiated NAFTP-sponsored first-line ART in
13 2008; having been ART-free before 2008; having been on ART for 36 ± 6 months in
14 2011; and providing consent to participate in the study.

15 Questionnaires administered by trained study personnel from provincial CDC in
16 private rooms using structured interviews collected data in 2011 and 2012. Each study
17 participant was assigned a confidential identification number used to label
18 questionnaire and blood specimen. Additional HIV-specific data including route of
19 transmission, initial ART regimen, latest ART regimen, ART distribution location and
20 CD4 cell count were collected from the 2011-2012 National HIV Surveillance

1 Database. There was no missing demographic data, missed questionnaire data was
2 feedbacked to local CDC for recollection at the time.

3 **Laboratory analysis**

4 Blood specimens were collected from all participants to determine CD4 cell count,
5 HIV-1 RNA viral load (VL), and HIV-1 drug resistance mutations in both 2011 and
6 2012. CD4 cell count estimation was conducted at provincial CDC laboratories using
7 flow cytometry (FACSC Calibur, BD Company, USA) within 24 hours after
8 specimen collection. Plasma was isolated and stored at -80°C at a provincial CDC
9 laboratory and then transferred to NCAIDS for testing HIV VL and drug mutation.
10 Plasma HIV RNA was quantified with real-time NASBA (NucliSense Easy Q,
11 bioMerieux, France) or COBAS (Roche Applied Biosystems, Germany) according to
12 manufacturer recommendations using in-house PCR (polymerase chain reaction),
13 both of the assays were performed automatically.¹⁹ Virologic failure was defined as
14 VL \geq 1000 copies/ml. According WHO protocol,²⁰ HIVDR tests were performed on
15 samples with VL \geq 1000 copies/ml. HIV-1 *pol* gene (protease 1-99 amino acids and
16 part of reverse transcriptase 1-252 amino acids) were amplified, purified and analyzed
17 using the Stanford HIV Drug Resistance Database (<https://hivdb.stanford.edu/hivdb>).
18 Levels of HIVDR were classified according to the algorithm of Stanford HIVdb
19 program. The scores are the sum of each mutation penalty score for a drug. Scores
20 less than 10 indicate susceptible; scores between 10 and 14 indicate potential low-
21 level resistance; scores between 15 and 29 indicate low-level resistance; scores

1 between 30 and 59 indicate intermediate resistance. Scores of 60 or greater indicate
2 high-level resistance. Any low-, intermediate-, or high-level resistance identified was
3 defined as HIVDR.²¹⁻²⁵

4 **Data analysis**

5 Questionnaire data were double-entered using Epidata 3.1 (The Epidata Association
6 Odense, Denmark). Statistical Analysis System (SAS 9.4, SAS Institute Inc., Cary,
7 NC, USA) was then used for data cleaning and analyses.

8 48-month risk for the outcomes of interest was calculated as the proportion of unique
9 persons who had experienced incident VF or HIVDR by the end of follow-up in 2012.

10 Covariates of interest were described using counts and percentages overall and by the
11 outcome of interest, stratified by gender. Univariate logistic regression models were
12 constructed to explore associations between covariates of interest and VF or HIVDR.
13 Odds ratios (OR) and 95% confidence intervals (CIs) are reported. Variables that
14 were significant ($P < 0.05$) in the univariate models were then fit into multivariate
15 logistic regression models assessment for removal of collinear variables that had the
16 weakest association with the outcome. Adjusted ORs (aOR) and 95% CIs were
17 presented. $P < 0.05$ was defined as statistically significant, and all tests were two
18 sided. Descriptive analysis on HIVDR mutation results was conducted among 27
19 HIVDR participants, stratified by sex.

20 **Results**

1 1100 subjects were selected using consecutive ID numbers from 2008 National
2 Surveillance Database; of those, 490 were lost follow-up by December, 2012. Among
3 those lost to follow up, 139 died, 55 emigrated, 134 lost contact, 17 refused to
4 participate, 65 stopped ART before 30 months, 36 transferred, 8 were under custody,
5 6 failed to provide a blood sample, 3 switched from ART to Tangcao tablet (an
6 antiviral Chinese herbal therapy), 2 became pregnant and switched to other regimens
7 and 1 was paralyzed. After excluding 74 participants for failing the eligibility criteria,
8 536 participants were included in the final 24-month analysis (Figure 1). The 48-
9 month risk of VF was 11.8% and risk of drug resistance was 5%.

10 Demographic and ART Information (Tables 1-2)

11 Of the 536 eligible participants, 51.8% were male; 76.5% were Han nationality; 45.0%
12 had an education level of elementary school or less; 56.2% were farmers; and 10.6%
13 were unemployed with the rest having regular income.

14 All regimens in this cohort remained 3TC-based from 2008 to 2012. Initiated
15 Nucleoside Reverse Transcriptase Inhibitors (NRTI) regimens included Zidovudine
16 (AZT) (n=349, 65.1%) or Stavudine (D4T) (n=187, 34.9%). 66 (12.3%) participants
17 later changed to TDF based regimen. Initiated Non-Nucleoside Reverse Transcriptase
18 Inhibitors (NNRTI) regimens included Nevirapine (NVP) (n=421, 78.5%) or
19 Etravirine (EFV) (n=115, 21.5%). 55 (10.3%) participants later changed to LPV/r
20 based regimen. 169 (31.5%) participants switched the initial ART regimen during
21 2008-2012, but no statistical significant difference was found in VF ($p=0.74$) and

1 HIVDR ($p=0.29$) risk between participants who switched regimens and participants
2 who did not switch regimens.
3 We found that 38.4% participants were hesitant to accept ART in the future, 36.8%
4 participants reported doubts whether ART was health promoting and 42.5%
5 participants did not report that poor ART adherence necessarily contributed to
6 HIVDR. Additionally, 40.5% of participants were not always satisfied with support
7 from friends or relatives. 472 (88.1%) participants reported not missing a dose in the
8 month prior to the date of the survey.
9 Multivariate model results (Table 3)
10 As shown in Table 3, minority male participants were at higher risk for both VF
11 (aOR=2.9, 95% CI: 1.1 to 7.3, P-value=0.02) and HIVDR (aOR=12.2, 95% CI: 1.8 to
12 84.8, P-value=0.01) compared to Han nationality male participants, while female
13 minorities were only at a higher risk for HIVDR (aOR=4.8, 95% CI: 1.2 to 19.7, P-
14 value=0.03).
15 Female participants initiating D4T-based regimens were at a higher risk for both VF
16 (aOR=2.5, 95% CI: 1 to 6.1, P-value=0.04) and HIVDR (aOR=3.6, 95% CI: 1 to 12.6,
17 P-value=0.05) versus those initiating an AZT-based regimen; interestingly, different
18 from their female counterparts, male participants showed no such association
19 (OR=0.6, 95% CI: 0.3 to 1.4, P-value=0.24). Also, female participants had a higher
20 risk of VF given adverse side-effects (aOR=2.3, 95% CI: 1 to 5.6, P-value=0.06).
21 Male participants with missed doses in the month prior to the survey were at a higher

1 risk of both VF (aOR=2.8, 95% CI: 1.1 to 7, P-value=0.03) and HIVDR (aOR=9.7, 95%
2 CI: 2.1 to 44.1, P-value<0.01) versus those without missed doses in the preceding
3 month. Conversely, missed doses in prior month was not significantly associated with
4 VF or HIVDR for women.

5 HIV Drug Resistance and Subtype (Table 4)

6 HIVDR identified in our study was consistency with the NFATP recommended ART
7 regimen. All 27 participants detected with drug resistance had NNRTI mutations, 21
8 (77.8%) had NRTI mutations. The dominant subtype was CRF07_BC for both males
9 (61.5%) and females (50%). All participants found with HIVDR had developed
10 HIVDR towards NNRTI; 85.7% male participants and 69.2% female developed
11 HIVDR toward NRTI; no Protease Inhibitor mutation was detected. There were no
12 CRF08_BC subtypes detected in the study population.

13 Discussion

14 The 48-month risk of VF was 11.8% and HIVDR was 5.0%, which indicated
15 relatively good treatment outcomes given meta-analysis suggested a 37-48 months
16 HIVDR prevalence ranging from 3.04%-47.92% in China,⁹ similar to studies in China
17 which estimated a one-year HIVDR incidence of 3.5% in 2009 and 2.1% in 2012.²⁶
18 ²⁷ Our study substantiates the finding that VF and HIVDR largely decreased since the
19 wide-spread of 3TC-based regimens.²⁸ Studies have shown mixed findings of gender
20 differences on ART adherence and treatment outcomes.^{14, 16, 29, 30} In our study, we
21 found male participants had slightly higher risk of VF (12.2% versus 11.2%, P-

1 value=0.72) but lower risk of HIVDR (4.7% versus 5.4%, P-value=0.69) than women.
2
3
4
5
6 Drug adherence and adverse effects influenced our outcomes differently for men
7
8
9 compared to women. Women's risks of VF and HIVDR were not associated with
10
11
12 missing doses in the past month, also, few women missed doses relative to men,
13
14 similar to two other studies in China suggesting women have better adherence
15
16 behaviors.^{31, 32} Male participants were at higher risk of both VF and HIVDR if they
17
18 reported missed doses. More detailed studies need to be conducted on the frequency
19
20 and factors associated with missing treatment. However, female participants showed a
21
22 higher risk of VF if they had adverse effect while men did not. This calls for further
23
24 research of what types of adverse effects are occurring and how they affect ART
25
26 adherence and virological outcomes across gender.
27
28 We found in this study that women, not men, who initiated D4T-based regimens were
29
30 more susceptible to VF (women vs. men OR=2.3 95% CI: 1.0 to 5.7 P-value=0.06)
31
32 and HIVDR (women vs. men OR=3.0 95%, CI: 0.8 to 11.3, P-value=0.11), consistent
33
34 with previous findings that D4T was more likely to increase the risk of mitochondrial
35
36 toxicity in women.^{33, 34} Mitochondrial toxicity caused by D4T had been reported to
37
38 cause many adverse effects such as lactic acidosis, lipodystrophy, and peripheral
39
40 neuropathy.^{35, 36} Following the WHO recommendation,³⁷ the NFATP advocated
41
42 switching the first-line regimen from D4T to TDF in 2012. The percentage of people
43
44 living with HIV initiating D4T-based regimen changed from 34.3% in 2010 to 10% in
45
46 2012 and 0.9% in 2014;³⁸ however, there were still 29.9% participants in our study
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 who were on D4T-based regimens in 2012. It was noteworthy that we did not see a
2 statistical difference in VF (OR=1.4 95%, CI: 0.4 to 4.2, P-value=0.60) and HIVDR
3 (OR=1.0, 95% CI: 0.2 to 4.2, P-value=0.98) between women who initiated and
4 remained on D4T-based regimens and those who switched to AZT/TDF based
5 regimens. It is possible that women switched regimens because of VF; however,
6 further studies need to be done to explore when to switch ART regimen for women
7 receiving D4T-based regimens. It is important to mention that data on ART adherence
8 and adverse effects were collected in 2012, when there were only four female
9 participants still using D4T-based regimens who experienced VF. The sample size
10 was not sufficient to explore whether D4T-based regimens affect drug adherence and
11 adverse effects for women.

12 Though not associated with the VF and HIVDR outcomes, 38.4% of study
13 participants reported that they would not 'always' be willing to take ART in the future,
14 36.8% reported not believing that ART is 'always' health promoting, and 42.5%
15 reported not believing that poor compliance 'always' contributed to HIVDR. As
16 willingness and these knowledge factors may impact more long-term VF and HIVDR
17 outcomes, the motivations behind willingness and knowledge about VF and HIVDR
18 warrant exploration.

19 Caution is needed when interpreting the study results from multivariate model that
20 older age (>45) was protective for HIVDR in men. There were only 4 male IDU
21 participants with older age (>45) in this study, the number is not sufficient to test for

1 interaction. There is no association between HIVDR and age (OR=6.5, 95% CI: 1.1 to
2 38.1, P-value=0.49) in the sub-analysis we did among male IDU participants , after
3 controlling for variables showed significant in the univariate model. A previous study
4 in HIV positive IDU population in China suggested that there is no association
5 between VF and sex or age.³⁹ In this study, 61.5% of male participants with HIVDR
6 became HIV infected via IDU, yet there were only 22.7% male IDU participants.
7 In addition, we found that younger (<45 years) IDU population were more likely to
8 miss doses (18.6%) compared to heterosexual transmission population (8.8%) and
9 blood transfusion transmission population (12.1%). This finding was consistent with
10 studies that implied younger males were at a higher risk of drug abuse.^{40, 41} This result
11 indicated that younger IDU population could be a main source of VF and HIVDR;
12 therefore they could be future targeted population for behavioral intervention.
13 The increased risk of VF and HIVDR in non-Han minorities, regardless of gender,
14 may be due to logistical, cultural, or social barriers faced by ethnic minorities which
15 limit their adherence to ART. It has been reported that minorities tend to have lower
16 social economic status than Han majorities, followed by lower education level and
17 fewer access to health facilities.⁴² It may be difficult for health professionals to reach
18 for some minorities because of their more remote geographic locations. Additionally,
19 several studies have reported that the percentage of high-risk populations such as
20 female sex workers (FSWs) and IDUs were higher in minorities than in Han
21 nationality.⁴³⁻⁴⁵ The causes of this increased VF and HIVDR risk warrants further

1 exploration, and ethnic minorities may be an important group to tailor adherence-
2 focused interventions in China. The finding that higher CD4 cell count at follow-up
3 was protective for VF and HIVDR was expected. NFATP changed treatment criteria
4 from CD4 cell count ≤ 200 cells/mm³ to CD4 cell count ≤ 350 cells/mm³ following the
5 WHO recommendation in 2011,^{7, 17, 46}. Our study indicated that male participants
6 who initiated treatment in 2008 at CD4 cell count ≥ 350 cells/mm³ were still at
7 higher risk towards VF (aOR=7.1, 95% CI: 1.1 to 45.8, P-value=0.04), supporting
8 possible clinical benefits of initiating ART at higher CD4 cell counts, < 500 cells/mm³
9 as per WHO recommendation in 2013.⁴⁷

10 Among participants infected by blood transmission, we only found HIVDR subtype B;
11 only one subtype C was found in participants infected with IDU, the dominant
12 subtype was CRF07_BC, found both in participants infected by heterosexual
13 transmission and IDU. The most common NNRTI mutation sites were K103N
14 (40.7%), K101E (22.2%) and V108I (22.2%); the most common NRTI mutation sites
15 were M184V (81.0 %) and K70R (19%). Interestingly, compared to a one-year
16 follow-up study in China with all participants initiated ART in 2011,⁴⁸ there is no
17 V108I in their study and we did not find K65R in our study.

18 Study findings should be interpreted in light of several limitations. Though we did not
19 account for transmitted drug resistance in this study, previous studies have found low
20 transmitted drug resistance risk ($< 5\%$) during this period⁴⁹⁻⁵¹ in China and we could
21 be fairly certain that participants were outcome free in 2008 as they were new ART

1 initiators. Another limitation of our study is that the outcomes were measured in 2011
2 and 2012, and thus we may be missing transient VF outcomes. Also, route of
3 transmission was collected in 2008 when assessing HIV infection among men who
4 have sex with men was not part of data collection instruments; additionally we do not
5 have data on sex worker status. Roughly half of the study participants selected for
6 possible inclusion in the study for having initiated first-line ART in 2008 were lost to
7 follow-up by 2012, creating a possible selection bias for individuals with better ART
8 adherence – this bias may underestimate the true VF and HIVDR risk and also limit
9 the generalizability of our findings to better adherers. Additionally, given the
10 demographic profile of the cohort, our findings are most generalizable to heterosexual
11 Han national who are married/cohabiting and working as agricultural labors in rural
12 areas. Misclassification of self-reported data is possible, though we do not expect this
13 misclassification to be differential by the outcome of interest and thus any such
14 information bias would bias our results toward the null.

15 **Conclusions**

16 We found female participants initiating D4T versus AZT-based regimens were more
17 vulnerable to VF and HIVDR, and we suggest future studies on whether and when to
18 change ART regimen for women initiated with D4T-based regimen. Poor adherence
19 was a risk factor among male participants who may benefit from reinforced adherence
20 counseling or social support. Increased VF and HIVDR risk among non-Han
21 minorities warrants further exploration, and ethnic minorities may be an important

1 group to tailor adherence-focused interventions in China. Also, this study indicated
2 that younger men who become infected through IDU may be groups to strategically
3 focus counseling and increased adherence support programs.

4 **Funding**

5 This study was supported by Guangxi Center for Disease Control and Prevention,
6 Nanning, China. The antiretroviral drugs used in this study were provided by NFATP.

7 **Contributions**

8 YR, WK, HX and YS designed the study. YR, HX, SL, LL, YM, HT, TZ, GS, HC,
9 WK, XL and PL collected the data. HC, TT and LL conducted laboratory analysis.
10 XL, WK analyzed the data. KW, VM, YR, WK, HX, LL and YS interpreted the data.
11 KW, VM, YR, WK, TT, and YS drafted the report. All authors reviewed, revised, and
12 approved the final report.

13 **Conflicts of Interest**

14 All authors declare that they have no conflicts of interest.

15 **Transparency Declarations**

16 Vincent C. Marconi has received fees from ViiV Healthcare.

17 **Conflicts of Data Sharing Statement**

18 No additional data available.

19

Table 1. Factors associated with virological failure (viral load ≥ 1000 copies/ml) stratified by sex

DEMOGRAPHIC FACTORS								
	Female				Male			
	Total	Virological failure Risk, N (%)	OR (95%CI)	P-value	Total	Virological failure Risk, N (%)	OR (95%CI)	P-value
Total	258	29 (11.2)			278	34 (12.2)		
Ethnicity								
Han nationality	191	19 (9.9)	1		219	20 (9.1)	1	
Other minorities	67	10 (14.9)	1.6 (0.7,3.6)	0.27	59	14 (23.7)	3.1 (1.5,6.6)	<0.01
Education								
Elementary school or less	134	15 (11.2)	1		107	12 (11.2)	1	
Junior school or more	124	14 (11.3)	1 (0.5,2.2)	0.98	171	22 (12.9)	1.2 (0.6,2.5)	0.68
Marital Status								
Single	59	6 (10.2)	1		75	9 (12)	1	
Married or Cohabited	199	23 (11.6)	1.2 (0.4,3.0)	0.77	203	25 (12.3)	1 (0.5,2.3)	0.94
Residence								
Rural	197	19 (9.6)	1		172	17 (9.9)	1	
City	61	10 (16.4)	1.8 (0.8,4.2)	0.15	106	17 (16)	1.7 (0.8,3.6)	0.13
Occupation								
Peasant	163	15 (9.2)	1		138	9 (6.5)	1	
Employee	64	11 (17.2)	2 (0.9,4.7)	0.09	114	17 (14.9)	2.5 (1.1,5.9)	0.03
Unemployed	31	3 (9.7)	1.1 (0.3,3.9)	0.93	26	8 (30.8)	6.4 (2.2,18.6)	<0.01
Age								

<35	73	6 (8.2)	1		53	7 (13.2)	1	
35-45	108	15 (13.9)	1.8 (0.7,4.9)	0.25	119	15 (12.6)	0.9 (0.4,2.5)	0.91
>45	77	8 (10.4)	1.3 (0.4,3.9)	0.65	106	12 (11.3)	0.8 (0.3,2.3)	0.73
Weight (kg)								
<50	89	14 (15.7)	1		49	7 (14.3)	1	
50-70	156	13 (8.3)	0.5 (0.2,1.1)	0.08	193	21 (10.9)	0.7 (0.3,1.8)	0.51
>70	13	2 (15.4)	1 (0.2,4.9)	0.97	36	6 (16.7)	1.2 (0.4,3.9)	0.76
HIV CHARACTERISTICS AND TREATMENT FACTORS								
Route of Infection								
Heterosexual Transmission	159	12 (7.5)	1		154	11 (7.1)	1	
Blood Transmission	86	13 (15.1)	2.2 (0.9,5)	0.07	61	10 (16.4)	2.5 (1,6.4)	0.04
Intravenous Drug use	13	4 (30.8)	5.4 (1.5,20.3)	0.01	63	13 (20.6)	3.4 (1.4,8)	0.01
Initial NRTI ART regimen								
AZT based regimen	161	11 (6.8)	1		188	26 (13.8)	1	
D4T based regimen	97	18 (18.6)	3.1 (1.4,6.9)	<0.01	90	8 (8.9)	0.6 (0.3,1.4)	0.24
Latest NRTI ART regimen								
AZT based regimen	181	15 (8.3)	1		195	27 (13.8)	1	
D4T based regimen	77	14 (18.2)	2.5 (1.1,5.4)	0.02	83	7 (8.4)	0.6 (0.2,1.4)	0.21
Switch ART regimen								
No	193	21 (10.9)	1		174	21 (12.1)	1	

Yes	65	8 (12.3)	1.2 (0.5,2.7)	0.75	104	13 (12.5)	1 (0.5,2.2)	0.92
ART drug distribution location								
County hospital or CDC	96	15 (15.6)	1		63	14 (22.2)	1	
Township hospital /village clinic /medication monitor	162	14 (8.6)	0.5 (0.2,1.1)	0.09	215	20 (9.3)	0.4 (0.2,0.8)	0.01
Adverse effects								
No	195	17 (8.7)	1		206	23 (11.2)	1	
Yes	63	12 (19)	2.5 (1.1,5.5)	0.03	72	11 (15.3)	1.4 (0.7,3.1)	0.36
CD4 cell/ml at baseline (2008)								
<350	244	28 (11.5)	1		272	31 (11.4)	1	
≥350	14	1 (7.1)	0.6 (0.1,4.7)	0.62	6	3 (50)	7.8 (1.5,40.2)	0.01
CD4 cell/ml at 36 months (2011)								
0-350	91	18 (19.8)	1		138	21 (15.2)	1	
≥350	167	11 (6.6)	0.3 (0.1,0.6)	<0.01	140	13 (9.3)	0.6 (0.3,1.2)	0.13
CD4 cell/ml at 48 months (2012)								
0-350	81	14 (17.3)	1		122	20 (16.4)	1	
≥350	177	15 (8.5)	0.4 (0.2,1)	0.04	156	14 (9)	0.5 (0.2,1)	0.06
DRUG COMPLIANCE FACTORS								
Missed doses								

in past month								
No	226	26 (11.5)	1		246	24 (9.8)	1	
Yes	32	3 (9.4)	0.8 (0.2,2.8)	0.72	32	10 (31.3)	4.2 (1.8,9.9)	<0.01
Willing to receive ART in the future								
Always	153	15 (9.8)	1		177	19 (10.7)	1	
Not always	105	14 (13.3)	1.4 (0.7,3.1)	0.38	101	15 (14.9)	1.5 (0.7,3)	0.32
Believe ART is health promoting								
Always	158	16 (10.1)	1		181	19 (10.5)	1	
Not always	100	13 (13)	1.3 (0.6,2.9)	0.48	97	15 (15.5)	1.6 (0.8,3.2)	0.24
Believe poor compliance contribute to HIVDR								
Always	139	16 (11.5)	1		169	19 (11.2)	1	
Not always	119	13 (10.9)	0.9 (0.4,2.1)	0.88	109	15 (13.8)	1.3 (0.6,2.6)	0.53
Degree of satisfaction on support of friends or relatives								
Always satisfied	153	15 (9.8)	1		166	17 (10.2)	1	
Not always satisfied	105	14 (13.3)	1.4 (0.7,3.1)	0.38	112	17 (15.2)	1.6 (0.8,3.2)	0.22
Frequency of taking drugs reminded by friends or								

relatives								
Often	172	19 (11)	1		168	22 (13.1)	1	
Not often	86	10 (11.6)	1.4 (0.7,3.1)	0.38	110	12 (10.9)	0.8 (0.4,1.7)	0.58
Frequency of taking drugs reminded by doctors								
Often	178	23 (12.9)	1		184	28 (15.2)	1	
Not often	80	6 (7.5)	0.5 (0.2,1.4)	0.19	94	6 (6.4)	0.4 (0.2,1)	0.03

*OR: odds ratio; CI: confidence interval; HIVDR: HIV drug resistance; ART: antiretroviral treatment; AZT: Zidovudine; D4T: Stavudine

Table 2. Factors associated with HIVDR (viral load ≥ 1000 copies/ml with drug resistance) stratified by sex

DEMOGRAPHIC FACTORS								
	Female				Male			
	Total	HIVDR Risk N (%)	OR (95%CI)	P-value	Total	HIVDR Risk N (%)	OR (95%CI)	P-value
	258	14 (5.4)			278	13 (4.7)		
Ethnicity								
Han nationality	191	6 (3.1)	1		219	5 (2.3)	1	
Other minorities	67	8 (11.9)	4.2 (1.4 to 12.5)	0.01	59	8 (13.6)	6.7 (2.1 to 21.4)	<0.01
Education								
Elementary school or less	134	5 (3.7)	1		107	5 (4.7)	1	
Junior school or more	124	9 (7.3)	2 (0.7 to 6.2)	0.22	171	8 (4.7)	1 (0.3 to 3.1)	1
Marital Status								
Single	59	4 (6.8)	1		75	4 (5.3)	1	
Married or Cohabited	199	10 (5)	0.7 (0.2 to 2.4)	0.60	203	9 (4.4)	0.8 (0.2 to 2.8)	0.75
Residence								
Rural	197	7 (3.6)	1		172	5 (2.9)	1	
City	61	7 (11.5)	3.5 (1.2 to 10.5)	0.02	106	8 (7.5)	2.7 (0.9 to 8.6)	0.09
Occupation								
Peasant	163	5 (3.1)	1		138	0	1	
Employee	64	6 (9.4)	3.3 (1 to 11.1)	0.06	114	9 (7.9)	2 (1 to 12.6)	<0.01
Unemployed	31	3 (9.7)	3.4 (0.8 to 15)	0.11	26	4 (15.4)	3 (1 to 13.4)	<0.01

Age								
<35	73	5 (6.8)	1		53	6 (11.3)	1	
35-45	108	6 (5.6)	0.8 (0.2 to 2.7)	0.72	119	6 (5)	0.4 (0.1 to 1.4)	0.15
>45	77	3 (3.9)	0.6 (0.1 to 2c.4)	0.43	106	1 (0.9)	0.1 (0 to 0.6)	0.02
Weight (kg)								
<50	89	8 (9)	1		49	4 (8.2)	1	
50-70	156	4 (2.6)	0.3 (0.1 to 0.9)	0.04	193	7 (3.6)	0.4 (0.1 to 1.5)	0.19
>70	13	2 (15.4)	1.8 (0.3 to 9.8)	0.47	36	2 (5.6)	0.7 (0.1 to 3.8)	0.64
HIV CHARACTERISTICS AND TREATMENT FACTORS								
Route of Infection								
Heterosexual Transmission	159	8 (5)	1		154	2 (0.6)	1	
Blood Transmission	86	4 (4.7)	0.9 (0.3 to 3.2)	0.9	61	3 (2)	3.9 (0.6 to 24.1)	0.14
Intravenous Drug use	13	2 (15.4)	3.4 (0.6 to 18.2)	0.15	63	8 (10.5)	11.1 (2.3 to 53.7)	<0.01
Initial NRTI ART regimen								
AZT based regimen	161	5 (3.1)	1		188	10 (2.9)	1	
D4T based regimen	97	9 (9.3)	3.2 (1 to 9.8)	0.04	90	3 (1.6)	0.6 (0.2 to 2.3)	0.47
Latest ART regimen								
AZT based regimen	181	8 (4.4)	1		195	12 (3.2)	1	
D4T based regimen	77	6 (7.8)	1.8 (0.6 to 5.5)	0.28	83	1 (0.6)	0.2 (0 to 1.5)	0.11
Switch ART regimen								

No	193	10 (5.2)	1		174	6 (3.4)	1	
Yes	65	4 (6.2)	1.2 (0.4 to 4)	0.76	104	7 (6.7)	2 (0.7 to 6.2)	0.22
Adverse effect								
No	195	9 (4.6)	1		206	10 (4.9)	1	
Yes	63	5 (7.9)	1.8 (0.6 to 5.5)	0.32	72	3 (4.2)	0.9 (0.2 to 3.2)	0.81
CD4 cell at baseline (2008)								
<350	244	14 (5.7)			272	12 (2.3)	1	
≥350	14	0	-	0.36	6	1 (5)	4.3 (0.5 to 40)	0.2
CD4 cell at 36 months (2011)								
0-350	91	9 (9.9)	1		138	11 (4.8)	1	
≥350	167	5 (3)	0.3 (0.1 to 0.9)	0.03	140	2 (0.7)	0.2 (0 to 0.8)	0.02
CD4 cell at 48 months (2012)								
0-350	81	7 (8.6)	1		122	11 (5.4)	1	
≥350	177	7 (4)	0.4 (0.1 to 1.3)	0.13	156	2 (0.6)	0.1 (0 to 0.6)	0.01
DRUG COMPLIANCE FACTORS								
Missed doses in past month								
No	226	13 (5.8)	1		246	6 (2.4)	1	
Yes	32	1 (3.1)	0.5 (0.1 to 4.2)	0.55	32	7 (21.9)	11.2 (3.5 to 35.9)	<0.01

* ART drug distribution location, Willing to receive ART in the future, Believe ART is health promoting, Believe poor compliance contribute to HIVDR, Degree of satisfaction on support of friends or relatives, Frequency of taking drugs reminded by friends or relatives, Frequency of taking drugs reminded by doctors are not displayed for no statistical significant difference between categorizes.

* OR: odds ratio; CI: confidence interval; HIVDR: HIV drug resistance; ART: antiretroviral treatment; AZT: Zidovudine; D4T: Stavudine

Table 3. Multivariate Models of Factors associated with virological failure (viral load ≥ 1000 copies/ml) and HIVDR (viral load ≥ 1000 copies/ml with drug resistance) stratified by sex

Variables	FEMALE				MALE			
	Virological Failure		HIVDR		Virological Failure		HIVDR	
	Adjusted OR (95%CI)	P-value	Adjusted OR (95%CI)	P-value	Adjusted OR (95%CI)	P-value	Adjusted OR (95%CI)	P-value
Total								
Ethnicity								
Han nationality			1		1		1	
Other minorities			4.8 (1.2 to 19.7)	0.03	2.9 (1.1 to 7.3)	0.02	12.2 (1.8 to 84.8)	0.01
Residence								
Rural			1					
City			2.4 (0.6 to 9.5)	0.22				
Age								
<35							1	
35-45							0.3 (0.1 to 1.4)	0.12
>45							0.03 (0 to 0.6)	0.02
Weight (kg)								
<50			1					
50-70			0.3 (0.1 to 1.1)	0.08				
>70			4.2 (0.6 to 30)	0.15				
Route of Infection								
Heterosexual Transmission	1				1		1	
Blood Transmission	1.2 (0.5 to 3)	0.74			1.8 (0.6 to 5.8)	0.33	7 (0.8 to 64.4)	0.09

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Intravenous Drug use	4.1 (1 to 17.7)	0.06			2.1 (0.8 to 5.4)	0.12	2.3 (0.3 to 16.1)	0.41
Initial NRTI ART regimen								
AZT based regimen	1		1					
D4T based regimen	2.5 (1 to 6.1)	0.04	3.6 (1 to 12.6)	0.05				
ART drug distribution location								
County hospital or CDC					1			
Township hospital /village clinic /medication monitor					0.5 (0.2 to 1.3)	0.18		
Adverse effect								
No	1							
Yes	2.3 (1 to 5.6)	0.06						
CD4 cell at baseline (2008)								
<350					1			
≥350					7.1 (1.1 to 45.8)	0.04		
CD4 cell at 36 months (2011)								
<350	1		1				1	
≥350	0.4 (0.2 to 1.1)	0.07	0.3 (0.1 to 0.9)	0.04			0.3 (0 to 1.9)	0.2
CD4 cell at 48								

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

months (2012)					
<350	1			1	
≥350	0.6 (0.3 to 1.6)	0.36		0.1 (0 to 1)	0.05
Missed doses in past month					
No			1	1	
Yes			2.8 (1.1 to 7)	0.03	9.7 (2.1 to 44.1) <0.01
Frequency of taking drugs reminded by doctors					
Often			1		
Not often			0.4 (0.2 to 1.2)	0.12	

* OR: odds ratio; CI: confidence interval; HIVDR: HIV drug resistance; ART: antiretroviral treatment; AZT: Zidovudine; D4T: Stavudine

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 4. HIV Drug Resistance and Subtype among 27 patients with HIVDR Mutation Detected at 2011 and/or 2012 stratified by sex

	FEMALE (%)	MALE (%)	MUTATIONS	N (%)
Overall	14	13		
Subtype				
B	5 (35.7)	3 (23.1)		
C		1 (7.7)		
CRF01_AE	2 (14.3)	1 (7.7)		
CRF07_BC	7 (50)	8 (61.5)		
Antiretroviral Drug				
Non-nucleoside reverse transcriptase inhibitors (NNRTI,any)	14 (100)	13 (100)	NNRTI Mutations(total)	27
Efavirenz (EFV)	14 (100)	13 (100)	V90I	1 (3.7)
Nevirapine (NVP)	14 (100)	13 (100)	A98G	2 (7.4)
Etravirine (ETR)	6 (42.9)	8 (61.5)	K101E	6 (22.2)
			K103N	11 (40.7)
			V106A	4 (14.8)
			V108I	6 (22.2)
			E138A	1 (3.7)
			V179D/F	3 (11.1)
			Y181C	5 (18.5)
			G190A	5 (18.5)
			H221Y	1 (3.7)
			P225H	3 (11.1)
			F227L	1 (3.7)
			M230L	1 (3.7)

Nucleoside reverse transcriptase inhibitors (NRTI,any)	12 (85.7)	9 (69.2)	NRTI Mutations(total)	21
Lamivudine (3TC)	12 (85.7)	9 (69.2)	A62V	1 (4.8)
Azidothymidine (AZT)	2 (14.3)	2 (15.4)	D67G	1 (4.8)
Tenofovir (TDF)	1 (7.1)	3 (23.1)	T69N	2 (9.5)
Stavudine (D4T)	3 (21.4)	3 (23.1)	K70R/Q	4 (19)
Didanosine (DDI)	5 (35.7)	3 (23.1)	V75I/M	2 (9.5)
Abcavir (ABC)	12 (85.7)	9 (69.2)	M184V	17 (81.0)
Emtricitabine (FTC)	12 (85.7)	9 (69.2)	T215N	1 (4.8)
			K219E/Q	2 (9.5)
Protease inhibitors (PI,any)	0	0	PI Mutations(total)	0

*NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitors; NRTI: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors; PI: Protease Inhibitor

References

1. Hong SY, Nachega JB, Kelley K et al. The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention. *Infectious disorders drug targets* 2011; **11**: 124-33.
2. Gabillard D, Lewden C, Ndoye I et al. Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration. *Journal of acquired immune deficiency syndromes* 2013; **62**: 555-61.
3. Montaner JS, Lima VD, Harrigan PR et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. *PloS one* 2014; **9**: e87872.
4. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. *The New England journal of medicine* 1999; **341**: 1865-73.
5. Wang X, Yang L, Li H et al. Factors associated with HIV virologic failure among patients on HAART for one year at three sentinel surveillance sites in China. *Current HIV research* 2011; **9**: 103-11.
6. Zhang F, Dou Z, Ma Y et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. *Annals of internal medicine* 2009; **151**: 241-51, W-52.
7. Chinese Center of Disease and Control. Manual of the National Free Antiretroviral Treatment, 2007 edition 2007.
8. People's Republic of China (2008) UNGASS Country Progress Report. *Beijing: People's Republic of China* 2007.
9. Liu H, Ma Y, Su Y et al. Emerging trends of HIV drug resistance in Chinese HIV-infected patients receiving first-line highly active antiretroviral therapy: a systematic review and meta-analysis. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2014; **59**: 1495-502.
10. Djarma O, Nguyen Y, Renois F et al. Continuous free access to HAART could be one of the potential factors impacting on loss to follow-up in HAART-eligible patients living in a resource-limited setting: N'djamena, Chad. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2014; **108**: 735-8.
11. DeGruttola V, Dix L, D'Aquila R et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. *Antiviral therapy* 2000; **5**: 41-8.

12. Liao L, Xing H, Su B et al. Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China. *Aids* 2013; **27**: 1815-24.
13. Hare AQ, Ordonez CE, Johnson BA et al. Gender-specific risk factors for virologic failure in KwaZulu-Natal: automobile ownership and financial insecurity. *AIDS and behavior* 2014; **18**: 2219-29.
14. Berg KM, Demas PA, Howard AA et al. Gender differences in factors associated with adherence to antiretroviral therapy. *Journal of general internal medicine* 2004; **19**: 1111-7.
15. Floridia M, Giuliano M, Palmisano L et al. Gender differences in the treatment of HIV infection. *Pharmacological research* 2008; **58**: 173-82.
16. Moore AL, Mocroft A, Madge S et al. Gender differences in virologic response to treatment in an HIV-positive population: a cohort study. *Journal of acquired immune deficiency syndromes* 2001; **26**: 159-63.
17. World Health Organization. Surveillance Of HIV Drug Resistance In Adults Receiving Art (Acquired Hiv Drug Resistance). Accessed July 2014. 2014.
18. Bennett DE, Myatt M, Bertagnolio S et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. *Antiviral therapy* 2008; **13 Suppl 2**: 25-36.
19. Gaydos CA, Rizzo-Price PA, Balakrishnan P et al. Impact of international laboratory partnerships on the performance of HIV/sexually transmitted infection testing in five resource-constrained countries. *International journal of STD & AIDS* 2011; **22**: 645-52.
20. Organization WH. World Health Organization Protocol for Population Based Monitoring of HIV Drug Resistance Emerging During Treatment and Related Program Factors at Sentinel Antiretroviral Therapy Clinics.
21. Jiang Y, Qiu M, Zhang G et al. Quality assurance in the HIV/AIDS laboratory network of China. *International journal of epidemiology* 2010; **39 Suppl 2**: ii72-8.
22. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2006; **42**: 1608-18.
23. Yan H, Yu H, Xing W et al. Development of a proficiency testing program for the HIV-1 BED incidence assay in China. *Scientific reports* 2014; **4**: 4512.
24. Zhong P, Pan Q, Ning Z et al. Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. *AIDS research and human retroviruses* 2007; **23**: 847-56.
25. !!! INVALID CITATION !!! .
26. Xing H, Wang X, Liao L et al. Incidence and associated factors of HIV drug resistance in Chinese HIV-infected patients receiving antiretroviral treatment. *PloS one* 2013; **8**: e62408.

- 1
2
3 27. Wang J, He C, Hsi JH et al. Virological outcomes and drug resistance in
4 Chinese patients after 12 months of 3TC-based first-line antiretroviral treatment,
5 2011-2012. *PLoS One* 2014; **9**: e88305.
6
7 28. Xing H, Ruan Y, Hsi JH et al. Reductions in virological failure and drug
8 resistance in Chinese antiretroviral-treated patients due to lamivudine-based regimens,
9 2003–12. *Journal of Antimicrobial Chemotherapy* 2015: dkv078.
10
11 29. Nicastrì E, Leone S, Angeletti C et al. Sex issues in HIV-1-infected persons
12 during highly active antiretroviral therapy: a systematic review. *The Journal of*
13 *antimicrobial chemotherapy* 2007; **60**: 724-32.
14
15 30. Puskas CM, Forrest JI, Parashar S et al. Women and vulnerability to HAART
16 non-adherence: a literature review of treatment adherence by gender from 2000 to
17 2011. *Current HIV/AIDS reports* 2011; **8**: 277-87.
18
19 31. Dou Z, Xu J, Jiao JH et al. Gender difference in 2-year mortality and
20 immunological response to ART in an HIV-infected Chinese population, 2006-2008.
21 *PloS one* 2011; **6**: e22707.
22
23 32. Sabin LL, Desilva MB, Hamer DH et al. Barriers to adherence to antiretroviral
24 medications among patients living with HIV in southern China: a qualitative study.
25 *AIDS care* 2008; **20**: 1242-50.
26
27 33. Wester CW, Okezie OA, Thomas AM et al. Higher-than-expected rates of
28 lactic acidosis among highly active antiretroviral therapy-treated women in Botswana:
29 preliminary results from a large randomized clinical trial. *Journal of acquired immune*
30 *deficiency syndromes* 2007; **46**: 318-22.
31
32 34. Goedecke JH, Micklesfield LK, Levitt NS et al. Effect of different
33 antiretroviral drug regimens on body fat distribution of HIV-infected South African
34 women. *AIDS research and human retroviruses* 2013; **29**: 557-63.
35
36 35. Feleke Y, Fekade D, Mezegebu Y. Prevalence of highly active antiretroviral
37 therapy associated metabolic abnormalities and lipodystrophy in HIV infected
38 patients. *Ethiopian medical journal* 2012; **50**: 221-30.
39
40 36. Moyle GJ, Nelson MR, Hawkins D et al. The use and toxicity of didanosine
41 (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT). *The*
42 *Quarterly journal of medicine* 1993; **86**: 155-63.
43
44 37. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and
45 Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva,
46 2013.
47
48 38. Dou Z, Zhang F, Zhao Y et al. Progress on China's national free antiretroviral
49 therapy strategy in 2002-2014. *Chinese Journal Epidemiology* 2015; **36**: 1345-50.
50
51 39. Leng X, Liang S, Ma Y et al. HIV virological failure and drug resistance
52 among injecting drug users receiving first-line ART in China. *BMJ open* 2014; **4**:
53 e005886.
54
55 40. Wu Z, Zhang J, Detels R et al. Characteristics of risk-taking behaviors, HIV
56 and AIDS knowledge, and risk perception among young males in southwest China.
57
58
59
60

1
2
3 *AIDS education and prevention* : official publication of the International Society for
4 *AIDS Education* 1997; **9**: 147-60.

5
6 41. Yang H, Li X, Stanton B et al. Heterosexual transmission of HIV in China: a
7 systematic review of behavioral studies in the past two decades. *Sexually transmitted*
8 *diseases* 2005; **32**: 270-80.

9
10 42. Myers Jr SL, Xiaoyan G, Cruz BC. Ethnic minorities, race, and inequality in
11 China: A new perspective on racial dynamics. *Review of Black Political Economy*
12 2013; **40**: 231.

13
14 43. Zoufaly A, Jochum J, Hammerl R et al. Virological failure after 1 year of first-
15 line ART is not associated with HIV minority drug resistance in rural Cameroon. *The*
16 *Journal of antimicrobial chemotherapy* 2015; **70**: 922-5.

17
18 44. Shou L, WANG QX, Lei N et al. The changing trends of HIV/AIDS in an
19 ethnic minority region of China: modeling the epidemic in Liangshan prefecture,
20 Sichuan Province. *Biomedical and Environmental Sciences* 2013; **26**: 562-70.

21
22 45. Zhang L, Zhu J, Rui B et al. High HIV risk among Uigur minority ethnic drug
23 users in northwestern China. *Tropical Medicine & International Health* 2008; **13**:
24 814-7.

25
26 46. Chinese Center for Disease Control and Prevention. Manual of the National
27 Free Antiretroviral Treatment, third edition. Accessed 2013 Jun 12. . 2013.

28
29 47. World Health Organization. *Consolidated guidelines on general HIV care and*
30 *the use of antiretroviral drugs for treating and preventing HIV infection:*
31 *recommendations for a public health approach*: World Health Organization, 2013.

32
33 48. Xing H, Ruan Y, Hsi JH et al. Reductions in virological failure and drug
34 resistance in Chinese antiretroviral-treated patients due to lamivudine-based regimens,
35 2003-12. *The Journal of antimicrobial chemotherapy* 2015; **70**: 2097-103.

36
37 49. Liao L, Xing H, Shang H et al. The prevalence of transmitted antiretroviral
38 drug resistance in treatment-naïve HIV-infected individuals in China. *Journal of*
39 *acquired immune deficiency syndromes* 2010; **53 Suppl 1**: S10-4.

40
41 50. Zhao K, Kang W, Liu Q et al. Genotypes and transmitted drug resistance
42 among treatment-naïve HIV-1-infected patients in a northwestern province, China:
43 trends from 2003 to 2013. *PloS one* 2014; **9**: e109821.

44
45 51. Su Y, Zhang F, Liu H et al. The prevalence of HIV-1 drug resistance among
46 antiretroviral treatment naïve individuals in mainland China: a meta-analysis. *PloS*
47 *one* 2014; **9**: e110652.


50 **Figure Legends**

51
52
53 Figure 1. Figure of exclusion on study cohort

54 1.Non-HIV related death
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Figure of exclusion on study cohort



1. None HIV-related death.

215x279mm (300 x 300 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Page	Recommendation
Title and abstract	1	2	(a) Indicate the study's design with a commonly used term in the title or the abstract
		2-3	(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction			
Background/rationale	2	5	Explain the scientific background and rationale for the investigation being reported
Objectives	3	6	State specific objectives, including any prespecified hypotheses
Methods			
Study design	4	7	Present key elements of study design early in the paper
Setting	5	7	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	7	(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
			<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls
			<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants
			(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed
			<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	8-9	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	9	Describe any efforts to address potential sources of bias
Study size	10	9	Explain how the study size was arrived at
Quantitative variables	11	9	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	9	(a) Describe all statistical methods, including those used to control for confounding
			(b) Describe any methods used to examine subgroups and interactions
			(c) Explain how missing data were addressed
			(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy
			(e) Describe any sensitivity analyses

Results

Participants	13*	9	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		9-10	(b) Give reasons for non-participation at each stage
		19	(c) Consider use of a flow diagram
Descriptive data	14*	10	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
			(b) Indicate number of participants with missing data for each variable of interest
		10	(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	10	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time
			<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure
			<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	11,9	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		8	(b) Report category boundaries when continuous variables were categorized
			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	14-15	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18	12	Summarise key results with reference to study objectives
Limitations	19	16	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	12-16	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	17	Discuss the generalisability (external validity) of the study results

Other information

Funding	22	18	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
---------	----	----	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.